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Abstract 
This thesis investigates the process of mitochondrial biogenesis in the rodent 
CNS  in  the  context  of  neuroinflammatory  and  neurodegenerative  disease. 
There is mounting evidence of mitochondrial damage in neuroinflammation 
but very little is known about the turnover of mitochondria in neurones. We 
developed a method to assess mitochondrial biogenesis by tagging replicating 
mitochondrial  DNA  with  bromodeoxyurine  (BrdU),  and  used  the  method  to 
examine  mitochondrial  biogenesis.  In  healthy  motor  neurons,  mitochondria 
were  distributed  throughout  the  cell,  including  the  axons,  but  the  DNA 
replication  signal  initially  only  appeared  in  the  cell  body,  subsequently 
becoming  distributed  away  from  the  soma  suggesting  the  presence  of  a 
mitochondrial  ‘nursery’  in  the  cell  body  of  long  neurones.  Furthermore, 
neuronal  DNA  replication  increased  in  response  to  raised  energy  demand 
resulting from unilateral electrical stimulation of the sciatic nerve, indicating 
that mitochondrial biogenesis is promptly responsive to energy demand.  
 
Mitochondrial  biogenesis  was  also  examined  in  spinal  cord  neurons  in  a 
model  of  multiple  sclerosis  (experimental  autoimmune  encephalomyelitis; 
EAE), and the degree of mtDNA replication was compared with the amount of 
inflammation  in  the  tissue.  We  found  that  in  severely  inflamed  tissue 
mitochondrial  biogenesis  was  significantly  reduced  in  the  motor  neurones. 
However, under subtle inflammation in EAE as well as with local intraspinal 	 ﾠ 6	 ﾠ
injection of LPS (lipopolysaccharide), there was an increase in mitochondrial 
biogenesis, which may be a compensatory mechanism.  
 
In  separate  experiments  the  CNS  was  examined  globally  using  the  BrdU 
method,  which  revealed  the  presence  of  hotspots  of  neuronal  mtDNA 
replication  indicating  marked  differences  in  mitochondrial  turnover. 
Interestingly,  these  hotspots  represented  regions  known  to  undergo 
degeneration in neurological diseases, especially those known or suspected 
to have a mitochondrial component in their aetiology. 
 
The  current  findings  reveal  that  mitochondrial  biogenesis  is  substantial  in 
neurons  with  long  axons,  and  that  it  is  promptly  responsive  to  changing 
energy and disease conditions.  
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Abbreviations 
5-HT  5-hydroxytryptamine (Serotonin) 
AD  Alzheimer's disease 
AMPK  AMP-activated protein kinase 
Ara-C  cytosine furanoarabinoside  
ATP  adenosine triphosphate 
BrdU  bromodeoxyuridine 
CA1   Cornu Ammonis 1 (Hippocampal Region) 
CA2  Cornu Ammonis 2 (Hippocampal Region) 
CA3  Cornu Ammonis 3 (Hippocampal Region) 
CGC  cerebellar granule cells 
ChAT  choline acetyl transferase 
CNS  central nervous system 
DA  Dark Agouti 
DG  dentate gyrus 
EBSS  Earle’s balance salts solution  
FBS  fetal bovine serum 
GFAP  glial fibrillary acidic protein 
HCl  Hydrochloric acid 
HD  Huntington's disease 
HIF-1α  hypoxia inducible factor - 1α 
MEM  modified Eagle's medim 
Mfn 1, 2  Mitofusin 1,2 	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mtDNA  mitochondrial DNA 
NeuN  Feminising Locus 
NRF-1,2  nuclear respiratory factor 
OCT  optimal cutting temperature 
OPA1  optic atrophy -1 
OPA2  optic atrophy -2 
OXPHOS  oxidative phosphorylation 
PBS  phosphate buffered saline 
PD  Parkinson's disease 
PDL  poly d-lysine 
PFA  paraformaldehyde 
PGC  PPAR coactivator  
PPAR  peroxisome proliferator activated receptor 
RC  respiratory chain 
ROS  reactive oxygen species 
SBTI  soybean trypsin inhibitor 
SN  substantia nigra 
SOD-1  superoxide dismutase 1 
TFAM  mitochondrial transcription factor A 
TH  tyrosine hydroxylase 
UCP  uncoupling protein 
VDAC - 1  voltage dependent anion channel - 1 
Vta  ventral tegmental area 
β III Tub  beta III tubulin 
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Chapter 1: Introduction 
Mitochondria are aptly termed the ‘powerhouses of the cell’ and are major 
contributors to the production of ATP – the energy molecule. ATP is the end 
product  of  a  series  of  pathways  predominantly  -  oxidative  phosphorylation 
(OXPHOS) and glycolysis. Mitochondria carry out OXPHOS via respiratory 
chain  complexes  arranged  on  the  inner  membrane  of  mitochondria.  Apart 
from this, mitochondrial are also the seat of many housekeeping functions of 
the cell, including biosynthesis of amino acids and steroids, β-oxidation of 
fatty  acids,  maintenance  of  cytosolic  calcium  homeostasis,  and  production 
and modulation of reactive oxygen species (ROS). Mitochondrial also play a 
vital  role  in  apoptosis  (Davis  and  Williams,  2012).  Considering  the  intense 
energy demands of neurones, improper functioning of mitochondria can have 
devastating effects on neuronal survival. There is ample evidence particularly 
from genetic forms of disease, to suggest that impaired mitochondrial function 
is  a  cause  rather  than  a  consequence  of  neurodegeneration  (Zsurka  and 
Kunz, 2013).  
 
Mitochondrial are double-membrane, dynamic organelles that are organized 
in a reticular network in the cell. They fuse and divide (fusion is mediated by 
OPA1, Mfn1, and Mfn 2, and fission is mediated by proteins fission 1 and 
Drp1),  fragment,  swell,  extend  and  are  recycled  (mitophagy  or  vesicle 
formation)  constantly  and  in  a  regulated  fashion.  Part  of  the  lifecycle  of 
mitochondria  also  includes  the  generation  of  new  mitochondria  known  as 	 ﾠ 15	 ﾠ
mitochondrial biogenesis – a process that is only beginning to be understood 
and  explored  in  the  context  of  disease.  Unbalanced  fusion  leads  to 
mitochondrial  elongation,  and  unbalanced  fission  leads  to  excessive 
mitochondrial fragmentation and small mitochondria, both of which impair the 
function of mitochondria. It has been shown that exchange of mitochondrial 
contents  is  important  for  mitochondrial  function  as  well  as  organelle 
distribution in neurons (Vidoni et al., 2013). Mitochondrial fusion, in particular 
that mediated by Mfn2, is required for proper development and maintenance 
of the cerebellum (Chen et al., 2007a). The picture that emerges is that the 
delicate balance between the different processes of fission, fusion, mitophagy, 
and  biogenesis,  is  crucial  for  the  functioning  of  the  mammalian  brain,  and 
particularly  in  maintaining  the  health  of  the  ageing  brain.  In  this  thesis,  I 
studied  the  rodent  central  nervous  system  to  shed  light  on  the  state  of 
mitochondrial  biogenesis  in  different  neuronal  types  and  in  different  tissue 
environments.  
Mitochondrial	 ﾠDNA:	 ﾠ	 ﾠ
Mitochondria  are  unique  organelles  in  that  they  are  the  only  extra  nuclear 
organelle  in  mammals  to  have  their  own  genome  -  mitochondrial  DNA 
(mtDNA). Mammalian MtDNA is a circular 16.5 kb molecule that encodes 13 
essential peptides of the oxidative phosphorylation system, the main source of 
ATP for the eukaryotic cell. Secondary mtDNA mutations are typically caused 
by defects in nuclear genes that encode mtDNA processing proteins or those 
affecting  nucleotide  pools,  leading  to  progressive  accumulation  of  mtDNA 
deletions or mtDNA depletion, and subsequently to mitochondrial respiratory 
chain (RC) deficiency. MtDNA maintenance defects have been shown to be a 	 ﾠ 16	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cause of neurodegenerative disorders (Corral-Debrinski et al., 1992). MtDNA 
replicates continuously in post-mitotic cells, but the mechanisms that regulate 
mtDNA  replication  initiation  and  copy  number  are  not  fully  understood. 
Likewise, the consequences of increased mtDNA amount in vivo are not well 
characterized. Two mtDNA maintenance proteins, mitochondrial transcription 
factor  A  (TFAM)  and  the  mitochondrial  helicase  Twinkle,  are  known  to 
correlate linearly with mtDNA copy number but the mechanisms involved are 
only  beginning  to  be  understood  (Ylikallio  et  al.,  2010).  Within  the 
mitochondria,  mtDNA  exists  as  multi-molecular  clusters  called  nucleoids. 
Nucleoid organization and mtDNA copy number are both important for the 
maintenance, inheritance and segregation of mtDNA.  
 
TFAM (mitochondrial transcription factor A)- a high-mobility group-box protein, 
is  an  activator  of  mitochondrial  transcription,  and  is  required  for  mtDNA 
replication, probably through providing RNA primers for replication. However, 
it also serves a histone-like function by packaging mtDNA, and, as mtDNA 
levels  follow  TFAM  levels,  it  is  likely  that  naked  mtDNA  does  not  exist  in 
mitochondria  (Kanki  et  al.,  2004).  Visualizing  TFAM  (via 
immunohistochemistry) can be a useful read-out for the amount mtDNA in a 
cell.  However,  this  is  not  a  good  indicator  of  mitochondrial  biogenesis 
because the method does not indicate whether the amount of mitochondrial 
DNA has increased or decreased as a result of the regulation of mitochondrial 
biogenesis or mitophagy.  
The  respiratory  chain,  which  is  responsible  for  the  process  of  oxidative 
phosphorylation,  ultimately  resulting  in  the  production  of  ATP  from  ADP, 	 ﾠ 17	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consists  of  complex  I–complex  IV.  The  mitochondrial  genome  holds  13 
protein-encoding genes, which incorporate into complex1, III, IV, complex and 
ATP synthase. Complex II is the only complex with all subunits encoded by 
only nuclear DNA(Taylor et al., 2004). MtDNA point mutations and deletions 
lead  to  energy  deficiency  states  frequently  affecting  the  central  nervous 
system (CNS) in patients with primary mitochondrial diseases (Goldstein et 
al., 2012).  
 
The maintenance of mtDNA is crucial for normal cellular function (Wallace et 
al., 1988). A unique feature of mitochondrial genetics is the coexistence of 
both  mutant  and  wild-type  mtDNA  in  a  single  cell.  Mutations  in  mtDNA 
accumulate over time and must reach a crucial threshold (~70-90% of total 
mtDNA)  before  associated  neurological  signs  manifest  (Wallace  and  Fan, 
2009).  Proper  mitochondrial  dynamics  are  important  for  the  accurate 
segregation and transmission of mtDNA during mitosis, and numerous studies 
in  yeast  have  shown  that  there  is  a  relationship  between  mitochondrial 
dynamics and genomic stability (Hermann and Shaw, 1998; Rapaport et al., 
1998).  The results of subsequent studies in mammalian cells agreed with 
these findings and confirmed the roles of Mfn1, Mfn2 and Opa1 in mtDNA 
maintenance (Chen et al., 2007a). 
 
It has been suggested that the exchange of mitochondrial contents mediated 
by mitochondrial fusion, enables the reduction of the influence of pathogenic 
mtDNA  mutations.  Introducing  wild-type  mtDNA  dilutes  the  mutant  mtDNA 
molecules  and  prevents  them  from  reaching  a  crucial  threshold  in  the  cell 	 ﾠ 18	 ﾠ
(Chen et al., 2007b; Sato et al., 2006, 2009) In a recent study conducted by 
Chen et al., muscle-specific Mfn1- and Mfn2-knockout mice were reported to 
have  impaired  mitochondrial  function,  abnormal  mitochondrial  proliferation 
and muscle loss (Chen et al., 2011). Furthermore, loss of mitochondrial fusion 
in skeletal muscle resulted in increased mtDNA point mutations and deletions 
as well as severe mtDNA depletion, which preceded the phenotypic changes 
observed  in  these  mutant  mice.  This  study  supports  the  hypothesis  that 
mitochondrial  fusion  through  intramitochondrial  exchange  increases  the 
tolerance  of  a  cell  to  mutant  mtDNA,  and  protects  the  integrity  of  the 
mitochondrial genome. Therefore, changes in the expression levels of both 
fusion and fission proteins can influence the mitotic segregation of mutant and 
wild-type  mtDNA,  and  might  be  an  important  factor  in  the  proliferation  of 
dysfunctional  mitochondria  that  is  observed  with  ageing  and  mitochondrial 
disease. Recently, it has also been postulated that the size and complexity of 
mtDNA nucleoid structure can influence mtDNA damage accumulation during 
ageing  of  many  somatic  tissues  (Bogenhagen,  2009).  Although  significant 
advances  have  been  made  in  understanding  the  role  of  mitochondrial 
dynamics in mtDNA transmission, segregation and stability, additional work is 
required  to  link  the  aging  process  directly  with  the  organization  of  mtDNA 
nucleoids and the proteins that regulate mitochondrial dynamics.  
 
So far no reports have been published about the mitochondrial biogenesis 
process  in  neuroinflammation  or  neurodegeneration,  largely  because  the 
process is not easy to probe in vivo.  The techniques that have been used in 	 ﾠ 19	 ﾠ
the  past  have  mostly  been  in  cell  cultures  (Calkins  and  Reddy,  2011a; 
Magnusson et al., 2003).  
The understanding of the mitochondrial biogenesis landscape in the central 
nervous  will  enable  the  exploration  of  whether  modulating  the  molecular 
mechanisms of biogenesis can facilitate the protection of neurones against 
their degenerative fate.  
Understanding  mitochondrial  biogenesis  from  non-
neuronal systems 
Research regarding mitochondrial biogenesis has been ongoing for decades. 
Whether it is intrinsic to mitochondria themselves (fully autonomous), wholly 
separate from preexisting mitochondria (nonautonomous), or somewhere in 
between (partially autonomous)—has been continuously addressed starting 
from biochemical lipid synthesis studies beginning 40 years ago (Dennis and 
Kennedy,  1972).  In  addition,  the  more  recent  findings  of  mitochondrial 
network  fission  and  fusion  events  has  turned  the  simplistic  concept  that 
damaged mitochondria can be replaced into an open debate on the precise 
definition  of  ‘replacement.'  Is  there  fission  of  existing  mitochondria  with 
selective  replacement  of  damaged  sections  and  constituents  or  complete 
replacement  of  proteins,  lipids,  and/or  mtDNA?  The  prevailing  sentiment 
generally supports a partially autonomous model of biogenesis (Michel et al., 
2012),
 wherein newly synthesized proteins and other components (e.g., lipids) 
are  incorporated  into  existing  mitochondria,  which  is  somehow  linked  to 
fission  to  restructure  and/or  divide.  Despite  these  limitations,  mitochondrial 
dynamics related to the term ‘biogenesis' can be assessed by the combined 
use of several outcomes, many of which are now investigated in the context of 	 ﾠ 20	 ﾠ
brain pathology.  
 
Mitochondrial  proteins  are  encoded  in  both  the  nuclear  and  mitochondrial 
genomes, necessitating transcriptional activation in both organelles for fully 
functional mitochondria. This bigenomic origin of mitochondrial proteins is well 
documented  and  several  critical  components  have  been  identified,  but  the 
exact  mechanism  and  coordination  of  intra-  and  extra-mitochondrial 
processes are still poorly understood. The mitochondrial transcription factor A 
(TFAM)  is  encoded  in  the  nucleus  and  is  required  for  initiation  of  mtDNA 
replication, initiation of transcription of mitochondrial-encoded genes, as well 
as  the  organization,  and  possibly  copy  number,  of  the  mtDNA  genome 
(Falkenberg et al., 2007). Although several other mitochondrial transcription 
factors  have  been  identified,  TFAM  appears  to  be  the  major  regulator  of 
transcription. The expression of TFAM is primarily under the control of the 
nuclear transcription factor NRF-1 (nuclear respiratory factor 1), which also 
induces the transcription of nuclear-encoded mitochondrial genes essential for 
the electron transport chain. The replication of mtDNA and the induction of 
both nuclear- and mitochondrial-encoded mitochondrial genes are necessary 
for mitochondrial biogenesis, and support the concept that induction of TFAM 
and possibly NRF-1 are indispensable elements in biogenesis. To this end, 
upregulation  of  Tfam  has  been  observed  under  several  neuroprotective 
settings (Mendelev et al., 2011). 
 
Various upstream signalling pathways can contribute towards the activation of 
the  transcriptional  programme  necessary  for  biogenesis.  PGC1- α 	 ﾠ 21	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(peroxisome  proliferator-activated  receptor  (PPAR)-γ  coactivator  1-α), 
nuclear factor-κB (NF-κB), and Nfe2l2 can translocate to the nucleus either 
by dissociation of tethering proteins or posttranslational modification, and are 
then capable of binding to the promoter region and promoting transcription of 
NRF-1. NRF-1 can then bind to and promote the transcription of mitochondrial 
transcription factor A (TFAM) and many other nuclear-encoded mitochondrial 
proteins, such as subunits of the electron transport machinery (Stetler et al., 
2012). These proteins are then translated and imported into the mitochondria. 
TFAM  then  can  bind  to  and  initiate  transcription  of  the  mitochondrial 
genomes,  which  includes  mitochondrial-encoded  subunits  of  the  electron 
transport  machinery.  Tfam,  in  addition  to  other  proteins,  also  acts  in  the 
control  of  mitochondrial  DNA  (mtDNA)  copy  number,  including  replication 
when needed (Ngo et al., 2014).  
 
Several elements of the above described pathway and associated proteins 
are  implicated  in  neurodegenerative  and  neuroinflammatory  conditions 
(Figure 1). However, what is not understood is: 
•  the constitutive rate of mitochondrial biogenesis in a neurone of interest 
•  whether this rate changes under the influence of changing metabolic 
demands  
•  whether modulating biogenesis can offer protection. 
BrdU – historical use / pharmacokinetics 
Bromodeoxyuridine (BrdU) is an often-used analogue of thymidine, which gets 
incorporated  into  the  de  novo  strand  during  DNA  synthesis  or  replication. 	 ﾠ 22	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Introduction of BrdU complimented with immunohistochemistry has been used 
extensively  to  study  cellular  proliferation  to  mark  the  nuclear  DNA  of  the 
replicating cell (Gratzner, 1982).  This method has proved to be a particularly 
powerful tool in the study of neural stem cell (Kee et al., 2002). Although BrdU 
has been used extensively for studying proliferation of nuclear DNA, it is not a 
common  probe  for  looking  at  mitochondrial  DNA  replication.  One  of  the 
reasons may be that the widely used dose of BrdU (100-200 mg/kg) in vivo for 
cell proliferation does not provide a sufficient concentration of BrdU in the 
tissue  to  probe  the  much  smaller  signal  for  mitochondrial  DNA.  The  other 
possibility is that there is very little mtDNA replication in most cells. The ability 
of BrdU to remain as part of the new strand of DNA provides a pulse and 
chase experimental tool, allowing the possibility of probing a specific point in 
time  and  space  to  evaluate  the  degree  and  pattern  of  mitochondrial  DNA 
replication and, in turn, mitochondrial biogenesis. This method has been used 
successfully in the past for cultured cell studies (Amiri and Hollenbeck, 2008; 
Davis and Clayton, 1996; Lentz et al., 2010; Magnusson et al., 2003).  
 
Incorporation of BrdU has been found to be deleterious to the fidelity of DNA, 
resulting  in  more  mutations  when  BrdU  containing  DNA  replicates  in 
subsequent  generations  (Duque  and  Rakic,  2011).  I  was  cautious  in 
interpreting the fate of BrdU containing mtDNA for this reason, because it may 
behave differently than naturally occurring mtDNA. For the purpose of this 
study we restricted our observations to using the BrdU signal as a simple 
readout  of  the  percentage  of  mitochondria  undergoing  DNA  replication.  All 	 ﾠ 23	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quantitative studies were made against physiologically comparable, controlled 
conditions.  
Mitochondrial pathology - neuroinflammation 
Multiple  Sclerosis  is  an  inflammatory  demyelinating  disease  of  the  CNS. 
Although  available  treatments  are  effective  in  controlling  the 
neuroinflammatory pathology, the loss in neuronal tissue which underlies the 
symptoms of the disease continues to progress. In recent years, evidence has 
emerged to suggest that infiltrating inflammatory cells and activated microglia 
contribute  towards  damage  to  neuronal  mitochondria  (Witte  et  al.,  2014), 
which  eventually  leads  to  axonal  loss  and  ultimately  neuronal  death. 
Mitochondria  were  implicated  in  MS  research  with  the  observation  that 
patients suffering from Leber’s hereditary optic neuropathy (LHON), which is 
caused by mutations in mtDNA (Wallace et al., 1988) have an increased risk 
of developing an MS-like condition known as Harding’s disease (Olsen et al., 
1995). Studies have suggested a weak association between LHON, mtDNA 
mutations  and  MS  susceptibility,  whereas  other  studies  failed  to  find  any 
association. There is evidence that the presentation of severe optic neuritis in 
a subset of MS patients is linked strongly to mtDNA mutations. This may be 
due to the relation of both MS and LHON to a certain mtDNA haplotype (a 
distinct set of mtDNA polymorphism (Kalman et al., 1999). 
 
So far one polymorphism in nuclear DNA encoding a mitochondrial protein 
has been linked to the susceptibility to MS. This was found to be associated 
with  MS  in  two  independent  cohorts  of  German  patients  in  the  promoter 	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region of uncoupling protein 2 (UCP2) a mitochondrial protein that is able to 
separate  the  mitochondrial  membrane  potential  from  ATP  synthesis  and 
thereby decrease ATP and ROS production (Vogler et al., 2005). As more 
whole genome sequencing is performed, it is likely that other mitochondrial 
proteins may be identified. In the meanwhile, it is important to get a handle on 
the mitochondrial turnover dynamics in multiple sclerosis and animal models 
of neuroinflammation – experimental autoimmune excephalomyelitis (EAE).  
 
It  was  reported  that  in  mice,  NRF-2  is  induced  in  neurones  by  the  drug 
dimethyl fumarate (DMF) (Linker et al., 2011). This effect has been proposed 
to contribute to an attenuated EAE disease course in DMF-treated mice, and 
might, therefore, partly underlie the beneficial effects of this drug in patients 
with  MS.  One  of  the  key  roles  of  NRF-2  is  to  increase  mitochondrial 
biogenesis along with NRF-1 via the PGC-1α pathway (Ventura-Clapier et 
al.,  2008a).  It  may  be  postulated  that  along  with  providing  antioxidant-
mediated  protection,  NRF-2  induced  mitochondrial  biogenesis  to  repair  the 
pool  of  damaged  mitochondria.  One  of  the  aims  of  the  present  work  is  to 
study the changes that occur to the rate of mitochondrial biogenesis under 
conditions of neuroinflammation.  
 
 Microarray  analysis  of  the  postmortem  motor  cortex  from  MS  patients 
revealed decreased gene expression of 26 nuclear-encoded subunits of the 
RC (Dutta et al., 2006), which coincided with a significant reduction in activity 
of  OXPHOS  complexes  I  and  III.  In  situ  hybridisation  showed  that  this 
decrease occurs specifically in cortical neurons. It was also observed that the 	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MS  cerebral  cortex  contained  neurons  devoid  of  complex  IV  activity 
(Campbell  et  al.,  2011).  However,  this  does  not  explain  the  reduction  of 
various nuclear-encoded respiratory chain complex subunits in the MS cortex 
(Dutta  et  al.,  2006).  The  overall  level  of  mitochondrial  biogenesis  may  be 
reduced  in  inflamed  tissue  and  we  explored  this  possibility  in  the  present 
work.  
 
 
Figure 1: Schematic showing the molecular pathways at play, which dictate 
the  mitochondrial  environment  in  the  diseased  CNS.  Stimuli  that  directly 
initiate biogenesis – oxidative stress, microglial activation, hypoxia are found 
to be active in neuroinflammatory and neurodegenerative disease. High levels 
of reactive oxygen species get released from damaged mitochondria and in 
turn activate the biogenesis machinery via signalling down the PKD and NF-
κB cascade. Similarly hypoxia can stimulate mitochondrial biogenesis via the 
SIRT1  signalling  pathway,  which  activates  PGC-1α,  one  of  the  master 
regulators of mitochondrial biogenesis.  
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Why study mitochondrial biogenesis? 
 Peroxisome proliferator-activated receptor (PPAR)-γ co-activator (PGC)-1α 
is  a  transcriptional  co-activator  that  interacts  with  a  broad  range  of 
transcription factors involved in a wide variety of biological processes and/or 
responses including mitochondrial biogenesis, OXPHOS, antioxidant defense, 
adaptive thermogenesis, glucose /fatty acid metabolism, fibre type switching 
in skeletal muscle, and heart development (Liang and Ward, 2006; Puigserver 
and Spiegelman, 2003; St-Pierre et al., 2006). PGC-1α does not bind to DNA 
directly, but forms heteromeric complexes with transcription factors, including 
nuclear  respiratory  factors,  NRF-1  and  NRF-2,  and  the  nuclear  receptors, 
PPARα,  PPARδ,  PPARγ,  and  estrogen-related  receptor  α  (Lin  et  al., 
2003). These transcription factors, in turn, regulate the expression of many 
nuclear-encoded mitochondrial genes, such as cytochrome c, complexes I to 
V, and TFAM (Handschin and Spiegelman, 2006; Kelly and Scarpulla, 2004). 
In recent years, impaired PGC-1α expression and/or function has emerged 
as  a  common  underlying  cause  of  mitochondrial  dysfunction  in 
neurodegenerative diseases such as Huntington’s disease (HD), Parkinson’s 
disease (PD), and Alzheimer’s disease (AD) and amyotrophic lateral sclerosis 
(ALS).  
  
 There  is  substantial  evidence  for  the  impairment  of  PGC-1α  levels  and 
activity in HD (Cui et al., 2006). The involvement of PGC-1α in HD was first 
indicated by the findings that PGC-1α knockout mice exhibited mitochondrial 
dysfunction, defective bioenergetics, a hyperkinetic movement disorder, and 
striatal  degeneration,  which  are  features  also  observed  in  HD  (Lin  et  al., 	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2003).  Selective  ablation  of  PGC-1α  leads  to  increased  striatal  neuron 
degeneration and increased susceptibility to the mitochondrial toxin 3-NP in 
HD  transgenic  mice  (Cui  et  al.,  2006).  Furthermore,  impaired  PGC-1α 
function and levels occur in striatal cell lines, transgenic mouse models of HD, 
and postmortem brain tissue from patients with HD ((Cui et al., 2006). This 
suggests that  dysfunctional mitochondrial biogenesis signal can underlie the 
pathology of the large scale neurodegeneration occurring in HD. 
 
It  is  not  understood,  why  certain  populations  of  neurones  are  far  more 
susceptible to damage and death. The symptoms which manifest the disease 
are related to the function of these neurones. One prime example of this is 
Parkinsons disease. A meta-analysis of 17 independent genome-wide gene 
expression microarray studies revealed the strongest association between PD 
and  nuclear  genes  encoding  for  OXPHOS  subunits  in  mitochondria  and 
enzymes involved in glucose metabolism, all of which are regulated by PGC-1
α (Zheng et al., 2010b). These genes showed decreased expression in (laser 
microdissected) substantia nigra dopaminergic neurons even in the earliest 
stages  of  PD.  Activation  of  PGC-1α  results  in  increased  expression  of 
OXPHOS  subunits  and  blocks  the  dopaminergic  neuron  loss  induced  by 
mutant  α-synuclein,  or  the  pesticide  rotenone,  in  cultured  dopaminergic 
neurons from embryonic rat midbrain and human catecholaminergic SH-SY5Y 
cells  (Zheng  et  al.,  2010b).  Transgenic  mice  overexpressing  PGC-1α  in 
dopaminergic neurons are resistant against cell degeneration induced by the 
neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Mudo et al., 	 ﾠ 28	 ﾠ
2012).  Earlier,  it  was  noted  that  genetic  ablation  of  the  PGC-1α  gene 
markedly  enhances  MPTP-induced  loss  of  tyrosine  hydroxylase-positive 
neurons in the substantia nigra (St-Pierre et al., 2006). Recently, a parkin-
interacting substrate was identified that accumulates in parkinsonian rodent 
models  and  the  human  PD  brain.  These  tissues  show  reduction  in  the 
expression of PGC-1α and its target gene, NRF-1 (Clark et al., 2011; Shin et 
al., 2011). Furthermore, there is some evidence of an association of certain 
PGC-1α single-nucleotide polymorphisms with the risk or age of onset of PD. 
This  suggests  that  perhaps  transcriptional  targeting  of  mitochondrial 
biogenesis may prove effective in protecting against PD pathology, leading to 
the question of why substantia nigra neurones are susceptible to damage. It 
was recently reported that selective mtDNA damage is a molecular marker of 
vulnerable  nigral  neurons  in  PD  and  suggested  that  this  may  result  from 
intrinsic  differences  in  how  these  neurons  respond  to  complex  I  defects 
(Sanders et al., 2014).  
  
 Using  genome-wide  complementary  DNA  microarray  analysis  (Qin  et  al., 
2009) showed that PGC-1α expression is decreased in the brain of patients 
with  AD  as  a  function  of  dementia  severity.  PGC-1α  protein  content  was 
negatively  associated  with  both  AD-type  neuritic  plaque  pathology  and  β-
amyloid contents. Qin et al. also showed that adenoviral-mediated exogenous 
PGC-1α expression in Tg2576 neurons attenuated hyperglycemic-mediated 
β-amyloidogenesis. Recently, Liang et al. (2011) showed an age-dependent 
decrease  in  PGC-1α  in  SOD1-G93A  mice.  Moreover,  they  showed  that 	 ﾠ 29	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overexpression  of  PGC-1α  slowed  the  progression  of  ALS,  moderately 
extended  lifespan,  and  improved  motor  (rotarod)  performance  (Liang  and 
Ward,  2006).  These  improvements  were  associated  with  a  significant 
decrease in motor neuron cell death and less neuromuscular junction damage 
in  the  G93A  mice  that  overexpressed  PGC-1α.  In  the  same  year,  the 
Pasinetti laboratory also showed that PGC-1α overexpression significantly 
improved motor function and survival of SOD1-G93A mice (Zhao et al., 2011). 
Reduced  blood  glucose  levels  and  protection  against  motor  neuron  loss, 
restoration of mitochondrial electron transport chain activities, and inhibition of 
stress signalling in the spinal cord accompanied the behavioral improvements.  
 
In light of the literature in the field this present study was set to lay the ground 
-work for studying mitochondrial biogenesis in vivo in the adult mammalian 
CNS,  with  the  hope  that  this  will  prove  beneficial  in  understanding  the 
important molecular players in modulating mitochondrial lifecycle and how this 
can be used for therapeutic benefit in the future. In the following chapters, 
along  with  a  brief  introduction  and  description  of  methodology,  four  key 
advances are presented:  
1.  Established a new method for probing mitochondrial biogenesis using 
mtDNA  replication  as  a  surrogate  marker  for  the  production  of  new 
mitochondria 
2.  Evaluated  mitochondrial  biogenesis  under  conditions  of 
neuroinflammation 
3.  Evaluated mitochondrial biogenesis under altered energy demand and 
discovered a somatic mitochondrial nursery in long motor neurones 	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4.  Finally, identified regions of the CNS which show constitutively high 
mitochondrial biogenesis  
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Chapter 2: Assessing 
mitochondrial DNA biogenesis in 
the CNS 
Introduction 
Mitochondria are key regulators of cellular energy and the focus of a large 
number of studies examining the regulation of mitochondrial dynamics and 
biogenesis  in  the  CNS,  both  in  healthy  and  diseased  conditions.  One 
approach  to  monitoring  mitochondrial  biogenesis  is  to  measure  the  rate  of 
mitochondrial  DNA  (mtDNA)  replication.  Here,  we  describe  a  sensitive 
technique to label newly synthesized mitochondrial DNA (mtDNA) in individual 
neurons  in  vivo  by  combining  incorporation  of  the  thymidine  analogue 
bromodeoxyuridine (BrdU). This technique is a valuable tool for visualizing 
and measuring mtDNA biogenesis within individual neurons, and importantly, 
in specific compartments such as somas, dendrites, axons, and synapses. 
This  is  the  first  report  using  BrdU  to  visualize  mtDNA  biogenesis  in  vivo, 
whereas other reports have used BrdU in vitro (Amiri and Hollenbeck, 2008; 
Lentz et al., 2010; Salic and Mitchison, 2008). The ability to visualize and 
quantify mitochondrial biogenesis will afford new insight into the mechanisms 
underlying  the  pathogenesis  of  multiple  mitochondrial-based  neurological 
disorders and here this method has been developed to study mitochondrial 
biogenesis  in  the  context  of  neuroinflammation.  BrdU  was  administered 	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systemically  and  the  signal  was  evaluated  post  mortem  via 
immunohistochemistry. We have found that in CNS tissue using this protocol 
the signal is observed mainly in neuronal cell bodies. The technique has been 
optimized for the rate of mitochondrial turnover in spinal cord motor neurones. 
Adult  neurones  are  post-mitotic  and  so  nuclear  DNA  replication,  which  is 
abundant  in  proliferating  cells,  is  absent  and  the  desired  neuronal 
mitochondrial replication can be observed very clearly. The BrdU signal was 
confirmed  to  be  arising  from  mitochondria  by  co-localization  with  a 
mitochondrial protein marker VDAC-1 (voltage dependent anion channel-1) 
and ensuring that these signals were extra-nuclear. The abundance of BrdU 
positive  mitochondria  as  a  percentage  of  the  total  VDAC-1  particles  was 
regarded as a of mitochondrial biogenesis in a cell. 
Furthermore,  the  reagents  used  in  the  protocol  were  evaluated  in  vitro  in 
cerebellar  granule  cell  cultures  in  order  to  validate  the  method  against 
previously  described  protocols.  Two  other  methods  were  evaluated  as 
supplementary to the BrdU protocol: first, immunohistochemical labeling for 
TFAM, which is a transcription factor that regulates mtDNA replication and, 
second,  labeling  with  PicoGreen®,  a  fluorescent  dye  that  intercalates  into 
double stranded DNA.  
Methods 
Preparation and injection of BrdU 
C57/BL6  mice  were  used  weighing  between  25-35  g.  Bromodeoxyuridine 
(BrdU)  (Sigma-Aldrich,  USA)  was  injected  at  different  doses  for  the  first 
experiment  testing  the  appropriate  dose:  100mg/kg,  200  mg/kg,  400mg/kg 
and then finally two doses of 200mg/kg spaced 2 hours apart. The BrdU was 	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dissolved in 0.9% sodium chloride solution in distilled water (saline), at 60°C 
in a water bath for 30 minutes just before injecting. The dosing volume was 
kept  constant  at  5  ml/kg.  Control  animals  were  injected  with  plain  saline. 
Injections were administered intra-peritoneally (i.p.) into the abdominal cavity 
of  the  animal,  alternating  sides  for  multiple  doses.  Animals  were  sedated 
lightly with isoflurane before injections (Figure 1). 
 
Figure 1: Timeline of BrdU injections. The different protocols were tested to 
optimize the optimum dose needed to detect mitochondrial DNA replication in 
spinal motor neurons.  
 
Perfusing, fixing, sectioning 
Animals were anaesthetised with 5% isoflurane and then maintained at 2% 
isoflurane, passed with 100% oxygen into a nose cone. Cardiac perfusion was 
performed using rinse (heparinized buffered saline) until the blood had been 
drained, and then 4% paraformaldehyde solution (PFA; in phosphate-buffered 
saline) until the tissue was structurally fixed. The carcass was decapitated to 
facilitate removing the brain and eyes. The spinal cord and nerve roots were 
dissected out separately. A piece of the small intestine was harvested as a 
positive control for the BrdU. The inner crypt layer of the intestine undergoes 
rapid cell proliferation and is a good marker for DNA replication. The samples 
were  post  fixed  in  4%  PFA  overnight.  The  samples  were  immersed  in 
increasing  concentrations  of  sucrose  (10%,  20%  and  30%)  for 	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cryopreservation. Each step was maintained as long as it was needed for the 
samples to sink into the solution to ensure that the sucrose solution had fully 
replaced the water content in the samples and the relative density across the 
solution  and  sample  was  in  equilibrium.  This  precaution  ensures  minimum 
freezing artifacts in the samples. Following this, the samples were dissected 
to appropriate smaller pieces and then placed in plastic molds and covered 
with OCT (Optimal Cutting Temperature compound, Tisse-Tek) tissue matrix 
gel. The molds were then frozen in a pot of isopentane pre-cooled in a bath of 
dry ice. The frozen molds were wrapped in aluminium and stored at -80 ̊C 
until sectioning. The samples were sectioned using a cryostat at -19 ̊C at a 
thickness of 12 µm on to positively charged glass slides. The glass slides 
were stored in sealed boxes at -20 ̊C before being processed and stained. 
Cell culture 
Cerebellar Granule Cell (CGC) Culture: Cerebellae were collected and CGCs 
were isolated as previously described by Courtney and colleagues (Courtney 
et  al.,  1990).  Five  day  old  Sprague  Dawley  rat  pups  were  sacrificed  and 
cerebellae collected on ice into a buffer consisting of 153 mM Na
+, 4 mM K
+, 
1.5 mM Mg
2+, 139 mM CL
¯, 10 mM PO4
2-, 1.5 mM SO4
2-, 14 mM glucose, and 
50 µM BSA (pH 7.4). This solution is called solution B. The cerebellae were 
chopped  up  with  a  sterile  razor  blade  and  collected  into  solution  B 
supplemented with 0.5 mg/ml trypsin to facilitate enzymatic digestion of the 
extracellular matrix. CGCs in trypsin were incubated for 5 minutes at 37
oC 
with gentle agitation every 1-2 minutes. Trypsin was neutralised by addition of 
20 ml of solution B containing 8 μg/mL soybean tryspin inhibitor (SBTI) and 8 
U/ml DNAase. The suspension was then centrifuged at 6 g for 5 minutes. The 	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supernatant was discarded, and the pellet resuspended and triturated in 3 ml 
of buffer (solution B containing 3 mM Mg
2+ and SO4
2- supplemented with 50 
µg/mL SBTI and 50 U/ml DNAase) using three fire-polished glass pipettes of 
progressively  decreasing  diameter.  Triturated,  homogenous  perikarya  were 
layered  onto  5  ml  4%  BSA  in  Ca
2+  -free  Earle’s  Balance  Salts  Solution 
(EBSS) and centrifuged for 5 minutes at 100 g to remove debris. The pellet 
was resuspended in warmed CGC medium (MEM supplemented with 10% 
FBS, 20 mM KCl, 30 mM D-glucose, 2 mM L-glutamine, 25 mM NaHCO4, 50 
U/ml penicillin, 50	 μM streptomycin, and 6μg/ml ampicillin) at a density of 
8x10
6 cells/ml. CGCs were then plated at 8x10
5 cells per well onto 13 mm 
diameter poly-D-lysine (PDL)-coated coverslips in a volume of 100μl media. 
To give perikarya time to adhere, additional CGC medium (400μl) was not 
added until at least 1 hour after plating (giving a total volume of 500μl per 
well). After 24 hours, the cells were washed and half the media was replaced 
with MEM supplemented with 20μM cytosine furanoarabinoside (Ara-C) to 
prevent further glial proliferation. The cultures were maintained at 37
oC in 6% 
CO2 and were available for use after 6 days in vitro. Either 1 µl or 0.5 µl of a 
BrdU  stock  in  saline  (10  mM)  was  added  into  the  medium  to  give  a  final 
concentration of 20 µM or 10 µM. The BrdU was left in the medium for a 
minimum of 6 h and maximum of 24 h. Control wells were treated with equal 
volumes of plain saline. 
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Immunohistochemistry / immunocytochemistry 
Immunohistochemistry: 
BrdU  was  detected  using  fluorescence  immunohistochemistry.  The  slide 
boxes  were  removed  from  the  freezer  and  allowed  to  warm  up  to  room 
temperature  before  opening  the  box,  in  order  to  avoid  condensation  and 
freezing on the slide. Then the sections were re-fixed with a few drops of 4% 
PFA on the slide for 15 minutes at room temperature. Phosphate buffered 
saline (PBS, sodium chloride 137 mM, potassium chloride 2.7 mM, di-sodium 
hydrogen  phosphate  10  mM,  potassium  di-hydrogen  phosphate  2mM,  pH 
adjusted  to  7.4)  containing  0.3%  TritonX-100  was  applied  to  partially 
permeabilize the cell membranes. After a five-minute PBS wash the slides 
were put in a trough containing 2 N hydrochloric acid (HCl) for 90 minutes at 
40 ̊C. The HCL partially denatures DNA in cells so as to expose the BrdU and 
allow the primary antibody access to the epitope. At the end of 90 minutes, 
the slides were washed with PBS once and then with PBS containing 0.3% 
hydrogen  peroxide  (from  30%  stock,  Sigma-Aldrich  USA)  to  quench  all 
endogenous  peroxidase  activity.  The  slides  were  then  laid  out  in  a  humid 
staining tray for further processing. Two washes for 5 minutes with PBS were 
performed following which 5% goat serum in PBS with 0.1% tween-20 was 
applied for one hour. The blocking serum buffer blocks the primary antibody 
from  interacting  with  non-specific  epitopes,  and  reduces  background.  After 
blocking, the slides were cleared of the solution simply by tilting them and 
then  primary  antibody  solution  in  PBS  was  added.  The  following  primary 
antibodies were used after optimization to determine the ideal dilution factors 
stated. 
1.  Rat anti BrdU (AbD Serotec MCA2060) at 1:200 	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2.  Rabbit  polyclonal  anti  VDAC-1  /  Porin  (Abcam)  ab15895  at 
1:600 
3.  Rabbit polyclonal Anti-NeuN (Abcam ab104225) at 1:500 
4.  Sheep  polyclonal  anti  choline  acetyltransferase  (Abcam 
ab18736) at 1:100 
5.  Mouse  monoclonal  anti  Beta  III  Tubulin  (Abcam  ab78078)  at 
1:400 
6.  Rabbit Polyclonal anti-TFAM (Abcam ab131607) at 1:400 
Slides  were  incubated  with  antibody  solutions  over  night  at  4 ̊C.  The  next 
morning, slides were washed stringently in troughs of PBS with 0.2% tween, 3 
times, 15 minutes each at room temperature. A combination of the following 
secondary antibodies in PBS were applied for 2 hours at room temperature 
1.  Biotinylated goat anti rat antibody at 1:200 (Vector labs BA-9401) 
2.  Biotinylated anti rabbit at 1:200 (Vector Labs BA-4001) 
3.  Goat anti rabbit conjugated to Alexa fluor 546 (Life Technologies 
A11081) at 1:400 
4.  Goat anti mouse conjugated to Alexa fluor 546 (Life Technologies 
A11003) at 1:400 
5.  Donkey  anti  mouse  conjugated  to  Alexa  Fluor  546  (Life 
Technologies A10036) at 1:400 
6.  Donkey Anti sheep conjugated to Alexa fluor 546 (Life Technologies 
A21098) at 1:400 
Slides were washed once again 3 times, each wash lasting 15 minutes with 
PBS  and  0.2%  tween.  Finally,  slides  were  incubated  for  90  min  at  room 
temperature with Alexa Fluor 488 conjugated streptavidin (Life Technologies 	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S-11223). After a final set of PBS washes, the slides were mounted using 
Vectashield (Vector labs H-1000) and then stored at 4 ̊C until ready to be 
imaged.  
 
To ensure that the streptavidin was not reacting with endogenous biotin, one 
set of slides was incubated with avidin (4 drops / ml) in the blocking serum 
followed by biotin (4 drops/ml) with the primary antibody step. This showed no 
difference in pattern of staining compared with the simpler protocol, so it was 
avoided for other protocols.  For staining that did not include BrdU the HCl 
acid treatment was replaced by a quick antigen retrieval step using DAKO 
target retrieval solution (S1700) for 40 minutes at room temperature.  
Immunocytochemistry:  
With the CGC cultures, the cells were incubated with BrdU (see above) for 
either 6 hours or 24 hours and then used the next day. Coverslips were kept 
in the 24 well plates for staining. Cells were fixed with 4% PFA in the wells for 
15 minutes at room temperature. Following this, phosphate buffered saline 
(PBS) containing 0.1% TritonX-100 was applied to partially permeabilize the 
cell membranes. After a five minute PBS wash 2N hydrochloric acid (HCl) was 
put in the wells for 90 minutes at 40 ̊C. At the end of 90 minutes, cells were 
washed  with  PBS  once  and  then  with  PBS  containing  0.3%  hydrogen 
peroxide (from 30% stock, Sigma-Aldrich USA). Two washes for five minutes 
with PBS were performed following which 5% goat serum in PBS was applied 
for  one  hour;  this  blocks  the  primary  antibody  from  interacting  with  non-
specific epitopes, and reduces background. After blocking, primary antibody 
solution in PBS was added. Primary and secondary antibody treatments were 	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carried out as described above in the stated dilutions. A 90 min incubation at 
room temperature with Alexa Fluor 488 conjugated streptavidin (Invitrogen) 
was followed with a final set of PBS washes. The coverslips were mounted on 
glass slides using Vectashield (Vector labs) and then stored at 4 ̊C until ready 
to be imaged.  
Image capture and analysis: 
Fluorescent  labelling  was  observed  through  a  LSM  5  Pascal  confocal 
microscope (Zeiss, Oberkochen, Germany) and images were recorded with 
the  Pascal  software  (Zeiss).  All  image  analysis  was  done  using  Image  J 
(NCBI, USA) and corresponding plug-ins. All staining was checked for non-
specific  antibody  labelling  using  control  slides  without  primary  antibody  or 
without  secondary  antibody  or  without  fluorescently  labelled  streptavidin.  
None of the controls showed any signs of nonspecific fluorescence.  
Staining with PicoGreen®  
PicoGreen®  (Life  Technologies  P7581)  was  used  to  try  and  quantify 
mitochondrial DNA in histological sections. Instead of using PFA-fixed tissue, 
this  tissue  was  fresh  frozen  and  sectioned.  The  sections  were  allowed  to 
warm up to room temperature and then PicoGreen® was added in PBS (3μl 
of  stock  in  1  ml)  and  applied  directly  onto  the  slides  for  15-30  minutes. 
Following this the slides were mounted with Vectashield and imaged on the 
confocal microscope within 24 hours  	 ﾠ 40	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Results 
Dosing regimen- 
Different  doses  of  BrdU  were  initially  tried  and  then  followed  up  with 
immunohistochemistry  to  visualize  extra-nuclear  DNA  replication.  The 
immunohistochemistry protocol was based on a previously described protocol 
with different antibodies (Calkins and Reddy, 2011b). The single doses of 100 
mg/kg of 200 mg/kg did not show any obvious non-nuclear BrdU incorporation 
into DNA in the CNS. The 400 mg/kg single dose showed some appearance 
of BrdU signal in the cytoplasm of neurons in spinal cord grey matter. When 
BrdU in saline is administered at 100 mg/kg i.p., the plasma concentration 
peaked at 2 hours and then slowly subsided after 4 hours (data not shown). 
On the basis of this pharmacokinetic profile, a new protocol was tested. First a 
loading dose of 200 mg/kg was administered, followed two hours later with 
another dose of 200 mg/kg (Figure 2).  
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Figure 2: BrdU staining (Green) performed on sections of spinal cord in order 
to detect mitochondrial DNA replication. Each panel is a representative image 
of motor neurones in transverse section of the ventral horn of spinal cord from 
an animal that received the following dose of BrdU (A) received 100 mg/kg, 
(B) received 200 mg/kg, (C) received 400mg/kg, and (D) received 2 doses of 
200 mg/kg.  
 
This particular dosing regimen showed clear extra-nuclear BrdU labelling in 
neurones of the spinal cord (Figure 2). To ensure that the BrdU signal was 
arising from mitochondria, a double labeling of BrdU and VDAC-1/porin was 
performed. VDAC-1 is used as a mitochondrial marker protein. In most cases, 
the  BrdU  co-localized  with  the  VDAC-1  signal,  but  not  on  every  occasion. 
Figure 3 shows these signals from grey matter of the spinal cord. The cells of 
primary interest are motor neurons of the spinal cord, which are particularly 
large  and  energy-demanding  neurons,  which  depend  on  a  robust  and 	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dynamic  mitochondrial  network  for  normal  functioning.  However,  it  is 
important to note that other cells in the CNS also do not show a large amount 
of BrdU in their cytoplasm indicating that the rate of replication of mtDNA is far 
greater in neurones as compared with other cells of the CNS.  	 ﾠ 43	 ﾠ	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Figure 3: Confocal image of a section through the ventral horn of the spinal 
cord showing labelling of mitochondria with VDAC-1 (red), BrdU (green) and 
co-localized signal in yellow. The plain green spots represent mitotic cells.  
This image demonstrates that it is possible to get DNA replication signal from 
mitochondria using BrdU. 
 
For subsequent experiments the 2 doses of 200 mg/kg were used along with 
an  enhanced  immunohistochemistry  protocol.  Two  steps  in  the 
immunohistochemistry were vital in achieving clear staining; first, 90 minute 
incubation in 2N hydrochloric acid at 40 °C and, second, amplification using 
biotinylated secondary antibody with streptavidin conjugated with Alexa Fluor 
488 (1:200). Without these two steps the signal was not clean even with a 
high dose of BrdU.  	 ﾠ 45	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Colocalisation with VDAC-1, ChAT 
Once the BrdU signal was confirmed to be arising from mitochondria, VDAC-1 
was  used  as  a  marker  of  the  abundance  of  mitochondrial.  The  extent  of 
mitochondrial  DNA  replication  was  assessed  as  the  fraction  of  VDAC-1 
positive  particles,  which  co-localized  with  BrdU  (Explained  in  detail  in 
Appendix) This analysis controls for the differences in mitochondrial content 
across cells attributed to differences in size or extent of arborization. In the 
following chapters similar analysis was performed in the where the extent of 
mitochondrial biogenesis was evaluated in different conditions where all other 
parameters of imaging and analysis were kept constant for images across 
experimental animals or samples.  
 
In the spinal cord most of the mitochondrial biogenesis observed was found to 
occur  in  the  cell  bodies  of  neurones.  The  identity  of  these  cells  was 
established to be motor neurons by collocating the extra nuclear BrdU signal 
with motor neuron marker acetylcholine transferase (ChAT) (Figure 4). 
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Figure  4:  Confocal  image  of  a  section  through  the  spinal  cord 
which shows that the small cytoplasmic BrdU signal (white arrows) 
appears in motor neurones as identified by ChAT labeling (red).  
 
In vitro validation – cerebellar granule cells culture 
In order to validate the in vivo mitochondrial DNA replication technique, we 
tried to recreate the methods using cultured cells. Primary cell cultures from 
the cerebellum containing both neurons and glia were subjected to 10 μM 
(Figure 5A) or 20 μM BrdU for 6 hours (Figure 5B), commensurate to the 
expected duration of the BrdU in vivo, and 24 h (Figure 5C) as previously 
described (Calkins and Reddy, 2011b). We found a large amount of labelling 
for extra nuclear BrdU. Controls with no BrdU showed no signal. At 6 h there 
was substantial labelling of mitochondrial DNA containing BrdU. With samples 
incubated with BrdU for 24 hours (Figure 5) there seemed to be very dense 	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signal,  suggesting  that  the  signal  was  correlating  with  the  duration  of 
exposure to BrdU. 
 
Figure 5: CGC cultures incubated with BrdU for 6 h or 24 hrs. BrdU (green) is 
seen  in  astrocyte  nuclei  as  bright,  saturated  signal,  and  cytoplasmic, 
mitochondrial  DNA  appears  as  small  green  dots.  The  red  marks  VDAC-1, 
which appears in neuronal cell bodies and processes.   
 
 In these cultures, the astrocytes continued to proliferate and, accordingly, an 
extremely strong BrdU signal was observed in the nuclei of astrocytes (Figure 
5).  In  order  to  image  clearly,  the  much  smaller  mitochondrial  DNA,  the 
detection  settings  on  the  confocal  microscope  were  optimized  to  collect  a 
large saturating signal from proliferating nuclei. Unlike astrocytes, the neurons 
did  not  undergo  cell  division,  and  the  entire  BrdU  signal  arose  from  non-
nuclear DNA. 
The identity of neuronal cells in culture was established by labeling for β-III 
tubulin to mark (Figure 6). 
10	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Figure 6: Confocal image of a CGC culture labelled with beta III tubulin, a 
neuronal  marker  (red),  and  BrdU  (green),  showing  small  cytoplasmic 
placement of BrdU in neuronal cell bodies.  
 
TFAM and PicoGreen®  
Immunohistochemical labelling of mitochondrial transcription factor A (TFAM) 
(Figure  7)  with  neuronal  marker  NeuN  can  be  used  to  determine  the 
mitochondrial content in a neurone. However, since TFAM is present on all 
mitochondrial DNA (Ngo et al., 2014) it is not as sensitive as BrdU in picking 
up the biogenesis signal. It does not specifically mark ‘new’ DNA. However, 
TFAM has the advantage that it is a good quick marker for large changes in 
mitochondrial biogenesis, and it is a useful tool because it does not require 
the harsh antigen retrieval steps required for the staining of BrdU and hence it 
presents an opportunity to counter label with several other antigens.  	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Figure 7: Confocal image of a section through the spinal cord labelled for 
TFAM  (green)  and  NeuN  (red),  co-localisation  in  yellow,  showing  an 
abundance of mitochondrial transcription factor in spinal neurones, supporting 
the possibility of fast turnover of mitochondrial DNA 
 
PicoGreen®  is  a  DNA  intercalating  fluorescent  dye  which  has  a  positive 
charge that allows it to accumulate inside mitochondria and thus specifically 
label mitochondrial DNA. Due to the nature of the interaction the fluorescence 
then attained from the cell is directly proportional to the content of DNA. This 
dye was tried as a way to quantify the amount of mitochondrial DNA content, 
in order to have an independent control against inherent differences in DNA 
content. Since the BrdU marks the extent of DNA replication, a change in 
content of DNA could confound the interpretation of results. However, due to 	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the loss of mitochondrial membrane potential in the dead tissue, the dye fails 
to  accumulate  solely  into  mitochondria  and  instead  a  very  large  signal 
appears from nuclear DNA, which overpowers any mitochondrial DNA signal 
(Figure 8). This dye was found not to be useful in quantifying mitochondrial 
DNA in post mortem mammalian tissue.  
 
 
Figure 8: Section of spinal cord stained with PicoGreen®. The signal from the 
nuclei is overbearing and there is no clear staining of mitochondrial DNA. The 
white arrow points to cytoplasmic staining of DNA, seen only in sporadic cells. 
Quantitation of the signal is not possible on account of saturating signal from 
nuclei and also inconsistent.  	 ﾠ 51	 ﾠ
Discussion 
In  the  present  study  we  showed  that  BrdU  can  be  used  as  a  marker  for 
mitochondrial DNA replication and thereby be used as a tool to study the life 
cycle of mitochondria in the mammalian CNS in vivo. While previous studies 
have used BrdU to target mitochondrial DNA in vitro and also ex vivo (Ashley 
et  al.,  2005),  this  particular  study  is  the  first  use  of  BrdU  along  with 
enhancements  in  immunohistochemical  methods,  allowing  an  investigation 
into the formation of mitochondrial DNA with spatial and temporal resolution in 
vivo.  
 
This  tool  now  presents  opportunities  to  interrogate  different  aspects  of 
mitochondrial biogenesis with respect to CNS pathology and physiology. In 
the next few chapters we investigate the extent of mitochondrial biogenesis in 
response to an inflammatory condition, namely EAE, and speculate about the 
importance  of  this  process  in  neuroinflammation  and  bioenergetics  in  the 
CNS. Following that we study the process in physiological processes such as 
increased  electrical  activity  in  the  periphery,  and  the  response  of  the 
mitochondrial biogenesis cascade to electrical activity. 
 
Co-labelling cells with BrdU and VDAC-1 is a sensitive measure of the growth 
of  the  mitochondrial  network.  In  conjunction  with  new  genetic  constructs, 
which mark the age of mitochondrial proteins such as MitoTimer® (Hernandez 
et al., 2013) this technique can provide powerful insights into the regulation of 
the  mitochondrial  network  turnover  and  its  implication  for  neurological 
diseases.  Almost  all  primary  mitochondrial  pathology  diseases  are 	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neurological  in  nature  and  this  rather  simple  technique  has  presented  an 
opportunity to elucidate aspects of the pathophysiology of these diseases 
 
A more sophisticated thymidine analogue, EdU, which has been previously 
described  to  be  an  alternate  method  for  studying  mitochondrial  DNA 
biogenesis (Lentz et al., 2010), could be developed as a way to study the 
process in vivo just as we have presented in this thesis. This will allow a 
larger number of cellular markers and antigens to be co-labelled with the DNA 
replicating signal. This is not possible using BrdU as the staining processes is 
very harsh and leaves little room for co-labelling other antigens. This is one of 
the major limitations of this thesis and the antigens presented in this work are 
more or less the only ones that are able to be co-labelled with BrdU amongst 
a battery of cellular markers that were tried. While using EdU may ease these 
problems,  the  cost  of  using  EdU  at  a  high  dose  in  vivo  along  with  the 
proprietary detection kit is prohibitive for the larger animal studies undertaken 
in this project.  
 
While  TFAM  provides  a  good  starting  point  for  detection  of  mitochondrial 
content  it  is  not  as  sensitive  as  BrdU  in  detecting  subtle  changes  in 
mitochondrial  biogenesis.  PicoGreen®  cannot  be  used  in  cryo-sections  as 
tested on samples. The BrdU method was found to be the most robust to 
evaluate mitochondrial biogenesis in vivo at an intracellular resolution, and to 
quantify  changes  amongst  neurones.  The  technique  has  definite 
shortcomings such as, the limitation on the number of antigens which can be 	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co-labeled  with  BrdU,  generation  of  unreliable  results  when  tested  in  a 
paradigm which inherently changes the mtDNA copy number in mitochondria, 
and  the  limitation  of  sensitivity  presented  by  immunohistochemistry. 
Considering  all  these  caveats,  we  used  the  BrdU  method  as  a  surrogate 
marker  for  mitochondrial  biogenesis  and  evaluated  the  cell  biology  of 
mitochondrial turnover and the extent of biogenesis in neuroinflammation.  
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Chapter 3: Mitochondrial 
biogenesis in neuroinflammation 
Introduction   
Mitochondria in MS 
MS is the most common demyelinating disease of the central nervous system 
and the most common disabling neurological disease affecting young adults. 
Demyelination in MS classically occurs with inflammation and is associated 
with axonal loss, which underlies neurological impairment in MS (Bjartmar and 
Trapp,  2003).  Demyelinated  lesions,  associated  with  various  degrees  of 
inflammation,  are  the  pathological  hallmarks  of  the  disease  and  they  have 
been studied since the 19th century. Axonal degeneration is most prevalent in 
active  lesions  where  inflammation  is  greatest.  In  chronic  lesions,  many 
surviving axons remain chronically demyelinated with only a few undergoing 
degeneration at any given point in time. 
 
Mitochondria are responsible for supplying the vast amount of ATP produced 
by oxidative phosphorylation in eukaryotic cells along with performing other 
key roles in calcium buffering and apoptosis (DiMauro and Schon, 2003). In 
the  CNS  mitochondria  play  a  particularly  important  part  because  neurons 
depend on the process of mitochondrial oxidative phosphorylation for most of 
their  supply  of  ATP  (Herrero-Mendez  et  al.,  2009).  The  observation  of 
increased mitochondrial presence within demyelinated axons raises a number 	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of important questions regarding how the mitochondrial changes occur (Witte 
et  al.,  2014).  Possible  explanations  include  an  increase  in  anterograde 
transport, decrease in retrograde transport, increase in fusion, decrease in 
fission, and mitochondrial biogenesis within axons. Neurons have developed 
a highly sophisticated transport system to meet the needs of the axon with 
machinery for both transport of proteins away from the cell body, into the far 
reaches  of  the  axon,  anterograde  transport,  and  a  system  to  transport 
aberrant proteins back to the cell body for degradation, retrograde transport 
(Saxton and Hollenbeck, 2012).  
 
Mitochondrial  activity  in  the  form  of  complex  IV  has  been  shown  to  be 
increased in inactive areas of chronic lesions associated with an increase of 
mitochondrial mass (Mahad et al., 2009; Witte et al., 2009). The expression of 
axon-specific  mitochondrial  docking  protein,  syntaphilin,  in  chronic  lesions 
indicates a potentially immobile reservoir that supplies the necessary energy 
in demyelinated axons (Mahad et al., 2008). Complex IV defects have been 
noted in both nonphosphorylated and APP-positive chronically demyelinated 
axons, with an associated decrease of mitochondrial mass in the former, but 
not the latter, case, which suggest differing mechanisms. Another study finds 
agreement  with  the  reduction  in  ATP  synthase  expression  in  MS  lesions 
(Smith  and  Lassmann,  2002).  Enhanced  immunoreactivity  of  the 
mitochondrial  heat  shock  protein  (mtHSP70)  in  chronic  lesions  has  been 
noted, indicating an environment of oxidative stress (Voloboueva et al., 2008; 
Witte et al., 2009). These findings point towards significant changes to the 
mitochondrial network  in MS, and since mitochondrial biogenesis may form a 	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key  element  in  the  life  cycle  of  mitochondria  it  is  important  to  study  this 
process.  In  this  context,  we  propose  to  study  mitochondrial  biogenesis  in 
neuroinflammation which will help understand in the process in MS.  
Mitochondrial Biogenesis 
In this study we focussed on studying spinal motor neurones as the pathology 
of our disease models (EAE and LPS injection) occurs in the grey matter of 
the spinal cord where these neurones are vulnerable to damage, which is 
implicated in the manifestation of symptoms. Their dependence on oxidative 
phosphorylation  makes  motor  neurones  especially  susceptible  to 
mitochondrial dysfunction, as evidenced by the preferential degeneration of 
motor  neurones  in  SOD1  motor  neurone  disease  although  SOD1  is 
ubiquitously needed for its protective actions against mitochondria-generated 
superoxide.  
 
Peroxisome  proliferator-activated  receptor-1α  (PGC-1α),  a  transcriptional 
coactivator, has been established to be the key moderator of mitochondrial 
biogenesis – it regulates the expression of ~19% of genes that are up- or 
down-regulated in caloric restriction (Corton et al., 2004). PGC-1α is found in 
brown adipose tissue and skeletal muscle, where it was first found to induce 
mitochondrial  biogenesis,  as  well  as  in  the  brain.  The  aforementioned 
stimulators of mitochondrial genesis indirectly increase PGC-1α expression in 
the nucleus. PGC-1α cannot bind to DNA on its own and instead binds to, and 
co-activates, nuclear respiratory factors 1 and 2 (NRF-1 and NRF-2). Their 
activation then induces expression of genes encoding mitochondrial proteins 
and, via mitochondrial transcription factor A, increases levels of mitochondrial 	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DNA (Jornayvaz and Shulman, 2010; Ventura-Clapier et al., 2008b). PGC-1α 
also  induces  biogenesis  by  interacting  with  oestrogen  related  receptors 
(ERRs).  ERRα  then  activates  transcriptional  activity  of  Mitofusin  2,  a 
mitochondrial membrane protein that is involved in mitochondrial fusion and 
regulates mitochondrial metabolism (Soriano et al., 2006). The culmination of 
these events is an increase in overall mitochondrial mass in a cell. Recent 
studies have demonstrated a link between defective mitochondrial biogenesis 
and increased risk of a whole host of neurodegenerative diseases such as 
Huntington’s, Parkinson’s and Alzheimer’s disease, and amyotrophic lateral 
sclerosis (Katsouri et al., 2012; Tsunemi and La Spada, 2012; Zheng et al., 
2010a).  Studies  have  found  altered  PGC-1α  levels  in  these  conditions, 
pointing  towards  a  possible  causal  role  for  dysregulated  mitochondrial  cell 
cycles in these diseases as PGC-1α is its master regulator (Liang et al., 2011; 
Tsunemi and La Spada, 2012). These studies have led to hypotheses that 
impairment in the regulation of mitochondrial dynamics might underlie other 
neurological diseases such as multiple sclerosis.  
 
One  of  the  key  inducers  of  mitochondrial  biogenesis  is  hypoxia.  Recent 
studies have shown that active EAE lesions are hypoxic and have increased 
expression of hypoxia inducible factor 1 α (HIF-1α) (Davies et al., 2013). HIF-
1α  is  a  regulator  of  PGC-1α,  which  in  turn  can  induce  mitochondrial 
biogenesis. Another inducer of mitochondrial biogenesis of particular interest 
is  oxidative  stress.  Neurological  deficits  seen  in  multiple  sclerosis  are  a 
consequence of inflammation-induced demyelination of axons. Myelin sheaths 
are vital for fast and energy-efficient saltatory conduction of impulses down an 	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axon;  when  the  sheath  is  compromised,  conduction  can  be  restored  by 
redistribution  of  voltage-gated  Na
+  channels  (van  Horssen  et  al.,  2012). 
Na
+/K
+  ATPase  activity  is  upregulated  to  restore  intra-axonal  Na
+ 
concentration following Na
+ leakage in previously myelinated segments of the 
axons; Na
+/K
+ ATPase are the largest consumers of ATP in the CNS, thus, 
their increased activity results in greatly increased ATP demand (Dutta and 
Trapp, 2007; van Horssen et al., 2012; Zambonin et al., 2011). This demand, 
together  with  the  generation  by  infiltrating  microglia  and  macrophages  of 
reactive oxygen species and nitric oxide, that can react to form peroxynitrite, 
results in an increase in mitochondrial biogenesis (Marik et al., 2007). At the 
same  time,  peroxynitrite-induced  damage  of  mitochondrial  DNA  results  in 
increased  and  dysregulated  mitochondrial  ROS  production,  impairing  the 
function  of  new  mitochondria  and  thereby  perpetuating  a  vicious  cycle.  If 
mitochondria are suppliers of ROS and of ATP, then here is where a problem 
lies: does the neurone continue production of mitochondria considering the 
fact that this in itself is ATP-dependent? If it does not, then this chronic energy 
deficiency will surely result in neuronal death. The present study has tried to 
evaluate whether neurones show an increase or decrease in mitochondrial 
biogenesis under varying extent of inflammation.  
 
EAE as a Model of Multiple Sclerosis 
Experimental  autoimmune  encephalomyelitis  (EAE)  is  an  animal  model  of 
autoimmune disease of the CNS that has been extensively worked on in the 
last 60 years. EAE is the most widely used experimental model of human 
multiple sclerosis, in part because of the resemblance of its pathology to that 	 ﾠ 59	 ﾠ
of MS: inflammation, demyelination and axonal loss and the occurrence of 
remyelination and resolution of inflammation (Lavi and Constantinescu, 2005). 
EAE’s susceptibility to variation of its clinical course with mode of induction 
and  host  species  also  makes  it  favourable  for  the  study  of  MS  as 
approximations of the different subtypes of MS can be induced and studied 
(Lavi and Constantinescu, 2005). In this study, a variation in combination of 
different  strains  of  rats  i.e.  Dark  Agouti  and  Brown  Norway  and  adjuvant 
produced a deteriorating form of EAE in one set of animals and a biphasic 
form in the other. This is detailed in the methods section below. Regardless of 
the  site  of  inoculation,  inflammation  always  progresses  rostrally  from  the 
caudal  end  of  the  rat  spinal  cord.  These  two  models  showed  a  different 
inflammation  profile  where  Brown  Norway  rats  had  higher  level  of 
inflammatory cells than the Dark Agouti rats at mild to medium neurological 
deficit. Furthermore, while the mitochondrial biogenesis was reduced in spinal 
neurones in high inflammation state in Brown Norways, in Dark Agouti rats 
there was an initial increase in mitochondrial biogenesis at mild to medium 
inflammation, suggesting a compensatory mechanism for energy deficit. We 
then followed up on this observation by studying the process of mitochondrial 
DNA  biogenesis  in  a  focal  model  of  neuroinflammation-  the  intraspinal 
injection of lipopolysaccharide (LPS).  
 
Intraspinal injection of LPS - model of neuroinflammation: 
In a disease such as multiple sclerosis, and its animal model EAE, immune-
mediated inflammation can be prominent but it is difficult to distinguish the 
indirect  consequences  of  the  inflammation  from  other  on-going  immune-	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mediated disease processes. Experimentally, inflammation can be induced in 
most tissues by the local injection of lipopolysaccharide (LPS), and typically 
large  numbers  of  neutrophils  and  monocytes  invade  the  tissue  from  the 
bloodstream within minutes, macrophages remaining at the site for a number 
of days (Issekutz et al., 1981). We have used this local inflammation from 
which the animals are known to recover as a model of active inflammation 
close to the site of the sciatic spinal neurones (ventral horn of spinal cord grey 
matter  in  the  lumbar  region)  to  observe  whether  there  is  an  increase  in 
mitochondrial biogenesis similar to what was observed in the Dark Agouti rats 
from EAE experiments. 
  
We  hypothesized  that  the  amount  of  mitochondrial  biogenesis  in  motor 
neurones in the EAE spinal cord correlates with the severity of inflammation in 
the  CNS.  We  studied  this  in  both  biphasic  (Dark  Agouti)  and  deteriorating 
(Brown  Norway)  forms  of  EAE  as  the  pattern  of  mitochondrial  biogenesis 
could  vary  according  to  disease  course.  We  also  corroborated  our 
observations in a focal model of inflammation. 
Methods 
EAE Studies: 
EAE was induced as previously established in the laboratory (Davies et al., 
2013).  The  N-terminal  sequence  (aa  1-125)  of  rat  recombinant  myelin 
oligodendrocyte glycoprotein (rrMOG; C. Linington, University of Aberdeen, 
UK) was used to induce EAE in young female DA rats (Harlan, UK; 109-150 
g).  For Dark Agouti rats (DA) a hard emulsion was prepared using 25% 2 
mg/ml rMOG, 25% saline and 50% incomplete Freund’s adjuvant (IFA). For 	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Brown Norway rats a similar preparation was made using complete Freund’s 
adjuvant (CFA). Control animals received injections of an emulsion prepared 
with 50% saline and 50% IFA/CFA alone. Animals were injected with 200 μl 
of the respective emulsions in the flank near the base of the tail. Therefore, 
the resulting dose of rMOG received by each animal was 100 μg. Twenty 
animals were induced with EAE in each strain of rats. 
 
Rats were weighed and examined daily through the course of the experiment. 
Neurological deficit was assessed using a 10-point scoring system, where the 
final score is an additive estimate of all the observable neurological signs. 
Rats were sacrificed at various presentations of neurological score, and were 
time-matched with controls.  All the controls presented with a score of 0 at the 
time of sacrifice. The animals were injected with BrdU (2x200 mg/kg) 24 h 
before sacrificing by cardiac perfusion (Figure 1). The following groups were 
used for analysis:  
•  Dark Agouti: score 0 (n=4 controls, n=4 asymptomatic), mild score 1-3 
(n=6), medium score 4-7 (n=5), severe score 8-9 (n=6) (N=25) 
•  Brown Norway: score 0 (n=3 controls, n=3 asymptomatic), mild score 
1-3 (n=5), medium score 4-7 (n=5), severe score 8-9 (n=5) (N=21) 
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Figure  2:  Timeline  of  conduction  of  EAE  experiments:  All  animals  were 
injected  either  with  rrMOG  or  vehicle  on  the  same  day.  Animals  were 
evaluated for deficit every day. At the first onset of symptoms, or at similar 
intervals in controls, animals were dosed with 200 mg/kg of i.v. BrdU and 
sacrificed by cardiac perfusion of rinse and 4% PFA. 
 
Intraspinal LPS injection: 
Adult  (250-350g)  Sprague  Dawley  (SD)  rats  were  anaesthetised  with  2% 
isoflurane (Merail, Harlow, UK) in 100% oxygen and the site of operation was 
shaved and sterilised with iodine. Subsequently, animals received a quarter 
laminectomy of the 13
th thoracic (T13-L1) vertebral element, the area where 
motor neurones of the sciatic nerve are located (Figure 3). Once the spinal 
cord was exposed, a small incision was made in the dura and pia, and 2 
injections  of  0.5  µl  of  LPS  (Salmonella  enterica  serotype  typhimurium  40 
ng/ml Sigma L-6143) were performed at 700 μm distance from the dorsal 
vein  and  a  depth  of  1100  μm  (Figure  3).  For  injections,  a  glass  drawn 
micropipette held in a micromanipulator with a trajectory of 24 degrees to the 
vertical was used. Injection sites were marked with a small amount of sterile 
charcoal. Control animals were injected with sterile PBS. Following this the 
animals were left to recover from surgery. Cohorts of animals were injected 
with  BrdU  (2x200  mg/ml  i.p.  in  saline)  at  24,  48,  72  and  96  hours  after 
surgery. Following BrdU, 24 hours later the animals were sacrificed by cardiac 	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perfusion. The control animals injected with PBS were dosed with BrdU at 72 
hours. For injections, a glass drawn micropipette held in a micromanipulator 
with a trajectory of 24 degrees to the vertical was used. Injection sites were 
marked with a small amount of sterile charcoal. Control animals were injected 
with sterile PBS. 
 
 
Figure 3: Cross section of spinal cord with a red arrow showing the pathway of 
the intraspinal injection of LPS into the ventral horn region of the spinal grey 
matter. The spots represent the motor neurone cell bodies. 	 ﾠ
 
Figure 4: This is a dissected spinal cord, which shows the site of injection of 
LPS into the lumbar region. The site coincides nicely with the area of the 
spinal cord that innervates the sciatic nerve.  
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Tissue Processing: 
Tissue  processing,  fixing  and  sectioning  was  performed  as  described  in 
Chapter 2.  
Immunohistochemistry: 
Immunohistochemistry was performed as previously described in Chapter 2. 
Additionally,  anti-CD68  (ED1)  antibody  (Abcam  ab31630)  was  used  at  a 
dilution of 1:200 to detect activated microglia and macrophages to evaluate 
the extent of inflammation in the tissue. Adjacent sections were stained for 
either a combination of VDAC-1 and BrdU in order to evaluate mitochondrial 
biogenesis and ED1 and TFAM.  
Image Acquisition 
Fluorescent  labelling  was  observed  through  a  LSM  5  Pascal  confocal 
microscope (Zeiss, Oberkochen, Germany) and images were recorded with 
the  Pascal  software  (Zeiss).  All  image  analysis  was  done  using  Image  J 
(NCBI, USA) and corresponding plug-ins. All staining was checked for non-
specific  antibody  labeling  using  control  slides  without  primary  antibody  or 
without  secondary  antibody  or  without  fluorescently  labelled  streptavidin.  
None  of  the  controls  showed  any  signs  of  nonspecific  fluorescence.  For 
imaging  VDAC-1,  BrdU  and  TFAM  sections  were  imaged  using  a  63x  oil 
objective with optical sections of 1 μm thickness. To evaluate the extent of 
ED1  labelling  the  entire  spinal  cord  section  was  scanned  using  a  20x 
objective to collate tiled images.  
Image Analysis  
Images  of  the  cell  bodies  of  motor  neurones  were  analysed  in  3D  stacks 
collected with optical sections 1μm apart and analysed using the plugin 3D 
Object  counter  using  FIJI  (ImageJ).  The  analysis  was  represented  as  the 	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percentage of particles of VDAC-1 which also showed positive labelling for 
BrdU.  Slides  from  every  animal  were  analysed  using  the  same  settings 
normalised against a positive control section from the intestinal region. Laser 
power, aperture size and PMT gain were kept consistent for the collection of 
images across the whole experiment. The threshold used for the analysis of 
particles was also kept consistent.  
To evaluate inflammation in the tiled images of ED1 labelling a threshold was 
set for fluorescence intensity and the area covered by positive labelling was 
measured using the ‘Measure-Area’ function in FIJI. This number was then 
normalized by the cross sectional area of the spinal cord section as measured 
by the area calculation after manually drawing the area of the spinal cord.  
Statistical	 ﾠanalysis:	 ﾠ	 ﾠ
Up to 80 motor neurone cell bodies were analysed using the above-described 
method  for  measuring  mitochondrial  biogenesis.  This  percentage  value  of 
mitochondrial biogenesis per cell was averaged for each animal. Then one-
way  ANOVA  test  was  performed  with  Bonferroni’s  test  to  evaluate  the 
significance. Similarly for the ED1 labelling, two sections were counted per 
animal  and  then  each  group  of  animals  was  averaged.  To  analyze  the 
numerical relationship between the extent of inflammation and mitochondrial 
biogenesis in the Brown Norway rats a scatter plot was made of the extent of 
inflammation against BrdU content per cell and then a curve was plotted using 
GraphPad Prism (Version 6) (Figure 9).  	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Results 
Assessing EAE pathology:    
Both sets of DA as well as BN rats with rrMOG-induced EAE exhibited severe 
inflammation in the spinal cord associated with a neurological deficit exhibited 
as  an  ascending  weakness  and  paralysis  of  the  tail  and  hindlimbs,  as 
previously  described  (Storch  et  al.,  1998).  Both  sets  of  animals  were  only 
evaluated at first onset of symptoms, however, animals exhibiting a spectrum 
of neurological deficits were used. The distribution of activated ED1 positive 
microglia and macrophages was estimated and found to correlate with the 
severity of neurological symptoms in Dark Agouti Rats (Figure 6). However, in 
the Brown Norway rats the distribution of ED1 positive cells was far greater at 
the onset of symptoms in animals presenting mild neurological deficit (Figure 
6). An ANOVA test showed a significant difference between the DA and BN 
rats  at  mild  and  medium  neurological  deficits  (p=0.0091,  n=35).  In  both 
groups  the  asymptomatic  animals  did  not  have  any  significant  amount  of 
inflammation present in the spinal cord (Figure 6).  
 
 
Figure  5:  Representative  images  of  spinal  cord  from  the  lumbar  region 
showing different degrees of inflammation Dark Agouti rats. Sections were 	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stained for ED1 marker and secondary antibody conjugated to red Alexafluor 
567. Images were captured using confocal microscopy and tiling with a 10x 
objective  lens.    (A)  Represents  an  animal  with  no  neurological  deficit.  (B) 
Represents an animal with very neurological deficit score 1. (C) Represents 
an animal with neurological deficit of score 4, and (D) represents an animal 
with severe deficit scored at 9.  The severity of neurological deficit correlates 
with the degree of inflammation. 
 
 
Figure 6: Quantitation of number of ED1 positive cells normalised for cross 
sectional area of the spinal cord. The blue bars represent an average of 5 
animals  per  group  of  different  neurological  deficits  (n=5).  The  naïve  and 
asymptomatic  animals  had  a  neurological  deficit  score  of  0.  Animals 
categorised as ‘mild’ had a neurological score between 1-3. Medium Severity 
included scores between 4 and 7. Severe deficit was defined as between 8 
and 10. A two-way ANOVA test was performed and at the mild and medium 
neurological deficit the Brown Norway rats showed significantly higher ED1 
positive cells compared with Dark Agouti rats. (p<0.01). 
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Mitochondrial DNA replication: 
Sections from the lumbar region of the spinal cord were stained for BrdU and 
VDAC-1 to evaluate the extent of mitochondrial biogenesis in spinal motor 
neurones as described in the Appendix. The spinal motor neurones showed 
clear colocalization of both signals in the cytoplasm as depicted in Figure 7A. 
Figures  7B,  and  7C  are  different  optical  sections  through  a  single  neuron 
showing that the BrdU signal arises from the cytoplasm and not the hollow 
nucleus.  Figure  7D  represents  BrdU  signal  alone  arising  from  nuclei  of 
proliferative cells in the spinal cord such as glial or precursor cells, showing 
that the signal is specific to replicating DNA.  
 
 
Figure 7: Representative image of VDAC-1(red) and BrdU (green) analysed in 
the grey matter of the spinal cord for mitochondrial biogenesis evaluation by 
normalising the yellow colocalization signal against total Porin content. (A) is a 
full stack of images collapsed into a flat z-project. (B) is a magnified single 
optical section through the cell indicated in (A) which clearly shows that the 
staining  is  perinuclear.  (C)  is  another  optical  slice  showing  dense 
arrangement  of  BrdU  staining  in  mitochondria.  (D)  The  green  only  signal 
appearing in this image represents non-mitochondrial BrdU.  
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Mitochondrial biogenesis in EAE: 
We  observed  a  difference  in  the  profile  of  change  in  the  signal  for 
mitochondrial  DNA  biogenesis  between  the  two  different  EAE  models 
evaluated.  The  Dark  Agouti  rats  showed  an  increase  in  mitochondrial 
biogenesis in animals with mild, medium or severe neurological deficits and 
inflammation.  In  contrast,  the  Brown  Norway  rats  had  a  decrease  in  the 
mitochondrial biogenesis signal as the neurological deficit increased (Figure 
9). The extent of neuroinflammation is relatively lower in the Dark Agouti rats 
at low neurological deficits and in order to ensure that a drop in the content of 
mitochondria does not cloud the signal from Brown Norway rats, a plot was 
made to show the correlation between inflammation and BrdU content and 
VDAC-1 (whole mitochondrial content) (Figure 9). Although with increasing 
neuroinflammation the content of mitochondria is reduced (blue line Figure 9), 
the  drop  in  BrdU  is  steeper  and  faster  (red  line  Figure  9)  suggesting 
specifically the production of new mitochondrial DNA has reduced and the 
observed signal is not just an artifact of a reduced number of mitochondria.  
The difference between the neuroinflammation in the Dark Agouti rats, which 
recover from the deficit from the first peak of disease and the Brown Norway 
rats,  which  do  not  recover  from  the  deficit,  was  curious  and  so  a  second 
recovery  model  of  focal  neuroinflammation  was  investigated  (intraspinal 
injection of LPS).  
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Figure 8:  Quantification of mitochondrial biogenesis. The blue bars represent 
an average of 5 animals per group of different neurological deficits. The naïve 
and  asymptomatic  animals  had  a  neurological  deficit  score  of  0.  Animals 
categorized as ‘mild’ had a neurological score between 1-3. Medium severity 
included scores between 4 and 7. Severe deficit was defined as between 8 
and 10. A two-way ANOVA test was performed and at the mild and medium 
neurological  deficit  the  Dark  Agouti  rats  showed  significantly  higher  BrdU 
positive  mitochondria  normalised  for  content  of  Porin  and  size  of  the  cell 
compared with Brown Norway rats. (p<0.0001) 
 
Naive
Asymptomatic
Mild 
Medium
Severe
0
20
40
60
80
100
Neurological Deficit
%
 
o
f
 
P
o
r
i
n
 
p
a
r
t
i
c
l
e
s
 
p
o
s
i
t
i
v
e
 
f
o
r
 
B
r
d
U
 
mtDNA replication in EAE
Dark Agouti
Brown Norway
** **	 ﾠ 71	 ﾠ
 
Figure 9: Scatter plot of the average BrdU content per cell in one section 
across different neurological scores, normalised for the size of cells body in 
spinal  cord  sections  of  Brown  Norway  EAE  rats.  The  corresponding 
inflammation in the tissue as measured by ED1 labeling. There is a steep 
decline of mitochondrial DNA replication as tagged by BrdU (red) but not of 
the  total  content  of  mitochondria  as  marked  by  VDAC-1  (blue)  in  Brown 
Norway rats.  
 
Intraspinal injection of LPS: 
In  agreement  with  previous  description  (Desai,  2013)  of  the  pathology 
resulting from intraspinal LPS injections in the ventral horn of the spinal cord 
of Dark Agouti rats, we observed the gradual build up of neuroinflammation 
with  activated  microglia  /  macrophages  (ED1  positive  cells)  in  the  first  48 
hours after LPS injection (Figure 10) and then this started to subside after 96 
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hours. On the other hand, mitochondrial biogenesis increased with high levels 
of  neuroinflammation  and  peaked  at  72  hours.  A  one-way  ANOVA  test 
showed a significant increase in mitochondrial DNA biogenesis at 48 hours 
and 72 hours compared with controls and with levels of biogenesis observed 
at 24 hours and 96 hours after injection of LPS (Figure 11). This result is 
similar to the observation of increased mitochondrial biogenesis in the Dark 
Agouti rats with EAE. 
The  distribution  of  mitochondrial  content  in  the  neurones  of  animals  that 
showed an increase in mitochondrial biogenesis was polarized towards the 
axon  hillock  (Figure  12)  as  evaluated  by  immunohistochemical  staining 
against TFAM. 
 
 
Figure  10:  Representative  images  of  spinal  cord  after  LPS  injection  in  the 
ventral horn labelled with ED1 (red) showing the progression of inflammation 
after. 	 ﾠ 73	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Figure 11: Along with increasing inflammation the amount of mitochondrial 
biogenesis also increases in the spinal cord of Dark Agouti rats after injection 
of LPS. A one-way ANOVA test was performed which suggests that at 48 
hours and 72 hours the mitochondrial biogenesis signal is significantly higher 
than at 96 hours and 24 hours and compared with vehicle injected animals 
(n=5, p<0.0001) 
 
72 Hours (no LPS)
24 hours
48 hours
72 hours
96 hours
0
20
40
60
80
BrdU motor neurones -LPS injection
%
 
o
f
 
P
o
r
i
n
 
p
a
r
t
i
c
l
e
s
 
p
o
s
i
t
i
v
e
 
f
o
r
 
B
r
d
U
 
**
**	 ﾠ 74	 ﾠ
 
Figure  12:  Representative  images  of  motor  neurones  labeled  with  TFAM 
(green). (A) is a motor neurone from tissue with no inflammation. (B) is a 
motor neurone from a spinal cord with lots of inflammation 72 h after injection 
of LPS. The mitochondrial content is polarized towards the axon hillock as 
observed by placement of the cell in the tissue section. 
 
Discussion 
It has been reported that mitochondrial DNA deletions at low levels in multiple 
sclerosis cortical grey matter expands to high levels in a proportion of neurons 
(Campbell et al., 2011). In primary mitochondrial disorders, the expansion of 
mitochondrial DNA mutations and respiratory deficiency are most notable in 
structures that are metabolically highly active, such as muscle fibres, choroid 
plexus  epithelium  and  neurons  (McFarland  et  al.,  2010).  An  increase  in 
mitochondrial  DNA  replication  rate  and  expansion  of  mitochondrial  DNA 
mutations (clonal expansion) has been proposed as a likely mechanism of 
tissue injury in these disorders. The supposed increase in energy demand of 
remyelinated and demyelinated axons is likely to influence the expansion of 
induced mitochondrial DNA deletions in multiple sclerosis. Such an intrinsic 
process is more likely to render neurons with remyelinated or demyelinated 
axons  respiratory  deficient  over  the  course  of  multiple  sclerosis  than 	 ﾠ 75	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myelinated axons. I suggest that my observations in the Dark Agouti rats and 
intraspinal  injection  of  LPS  suggest  that  an  increase  in  mitochondrial 
biogenesis  concurrent  with  a  neuroinflammatory  insult  may  result  in  an 
exacerbation of the clonal expansion of mitochondrial DNA defects. It may be 
speculated  that  the  imbalance  between  autophagy  and  biogenesis  might 
render  a  cell  vulnerable  to  accumulating  mitochondrial  damage  faster  in 
neuroinflammatory disease.  
 
The changes in axonal mitochondrial content following demyelination were at 
first thought to be potentially detrimental to axons but now are increasingly 
recognized  as  a  compensatory  mechanism  (Campbell  and  Mahad,  2011; 
Witte  et  al.,  2014).  In  light  of  this,  studying  the  mitochondrial  biogenesis 
regulation and changes in MS are increasingly important.  
 
Several pharmaceutical modulators of mitochondrial biogenesis, most notably 
PPAR-ϒ  agonists  (Chaturvedi  and  Beal,  2008),  are  being  tested  in 
neurodegenerative  diseases  such  as  Parkinson’s  and  are  proving  to  be 
efficacious enough to warrant clinical trials for neuroprotection. These drugs 
may prove beneficial in MS as well. The mitochondrial biogenesis tagging by 
BrdU will enable us to develop a robust in vivo pharmacodynamic pre-clinical 
biomarker model to test the efficacy of these drugs.   
 
It has been found that mitochondrial biogenesis is rapidly increased following 
neuronal injury resulting from hypoxic-ischaemic (HI) brain injury in rats (Yin 
et  al.,  2008).  There  were  increased  levels  of  mitochondrial  transcription 	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factors  TFAM  and  NRF-1  as  well  as  a  corresponding  increase  in  relative 
amount  of  brain  mtDNA  in  the  brain  of  rats  after  HI  injury.  As  one  of  the 
hallmarks  of  EAE  is  inflammation  of  the  CNS,  it  is  likely,  then  that  this 
endogenous CNS repair mechanism seen in HI brain injury also occurs in 
EAE. Yin et al. postulated that this increase in mitochondrial biogenesis forms 
part of an endogenous CNS repair mechanism, which is likely to also be the 
case in the EAE spinal cord.  
 
MS lesions are characterized by white matter plaques containing activated 
macrophages and microglia that, in one way or another, cause demyelination 
and transection of axons (Dutta and Trapp, 2007; Trapp et al., 1998). Axonal 
demyelination in the early phases of disease results in a large increase in 
energy  utilization  to  counteract  the  loss  of  energy-efficient  saltatory 
conduction. The EAE model of MS can also involve extensive demyelination 
(Lavi and Constantinescu, 2005), so it may be postulated that this increase in 
energy demand also occurs in EAE. The increase in mitochondrial number in 
a cell is likely to increase the metabolic capacity of a cell, thus bringing it out 
of  virtual  hypoxia  –  the  condition  of  energy  demand  outstripping  supply  in 
spite  of  sufficient  perfusion.  Mitochondrial  biogenesis  is  increased  as  if  to 
recover  normal  function  of  motor  neurones,  hence,  the  more  inflammatory 
damage  sustained  by  neurones,  the  more  mitochondrial  biogenesis  is 
upregulated.  It  is  likely  that  the  remission  phase  of  the  disease  is  a 
manifestation  of  this  mechanism  as  neurological  function  is  recovered, 
indicating that widespread neuronal cell death has been averted and recovery 
has been successful.  	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One  of  the  reports  that  supports  this  hypothesis  is  the  finding  that  the 
decreased activity of mitochondrial complex I is accompanied, and possibly 
compensated, by an increase in complex IV activity in chronic MS lesions 
(Dutta  and  Trapp,  2006).  Perhaps  the  upregulation  of  complex  IV  activity 
constitutes  part  of  an  endogenous  compensatory  mechanism  aimed  at 
increasing  neuronal  viability  and  function  by  increasing  the  number  of 
respiratory  chains  available  for  oxidative  phosphorylation,  and  that  is 
mimicked in our animal model of MS.  
 
This argument is further strengthened by recent evidence that mitochondrial 
biogenesis  improves  neurone  viability  under  ischemic  conditions  in  vitro 
(Stetler  et  al.,  2012).  When  deprived  of  oxygen  and  glucose,  neuronal 
upregulation of mitochondrial biogenesis by LPS pre-conditioning results in 
increased viability. These conditions, while not identical to the conditions in 
inflammation,  are  a  close  approximation  because  energy  supply  does  not 
meet  demand  in  both  situations.  The  authors  showed  that  inhibiting 
mitochondrial biogenesis by knocking down TFAM, a transcription factor vital 
for  the  initiation  of  mitochondrial  DNA  replication,  resulted  in  significantly 
decreased  neuroprotection  (Stetler  et  al.,  2012).  This  mechanism  of 
neuroprotection  is  likely  to  have  been  triggered  in  the  Dark  Agouti  rats  to 
return the health and function of neurons to baseline. However, it is important 
to note that the results of Stetler et al.’s study was based on neuronal cell 
culture, and that it is likely that factors such as multi-cascade interaction could 
alter the mitochondrial dynamics in an animal spinal cord (Stetler et al., 2012).  	 ﾠ 78	 ﾠ
 
While in the study described by Yin and colleagues there is an increase in 
expression of TFAM very shortly after stimulation (peaks 9 to 24 hours after 
assault), the timeframe for recovery of neurological function after first peak of 
disease in EAE is several days. This difference could be due to the acuteness 
of  hypoxia  in  the  Yin  et  al.  experiment  compared  to  chronic  nature  of 
inflammation  in  EAE.  Another  explanation  for  this  difference  in  time  to 
recovery could be a result of the complex and multiple processes - removal of 
damaged proteins, synthesis of new proteins and replacement of damaged 
oligodendrocytes  -  that  need  to  occur  before  neuronal  function  can  be 
restored.  
 
Mitochondrial biogenesis in progressive EAE 
I  observed  a  decrease  in  mitochondrial  DNA  biogenesis  in  symptomatic 
Brown  Norway  rats  with  progressive  EAE.  A  closer  look  revealed  that 
mitochondrial biogenesis also varied negatively with increasing neurological 
impairment. These results correlated well with my other demonstration that 
mitochondrial  biogenesis  decreased  exponentially  with  increasing 
inflammation. Dark Agouti rats tend to have episodes of disease interspersed 
by periods of disease remission whereas Brown Norway rats have a more 
progressive disease with little to no remission throughout the disease course 
(Lavi and Constantinescu, 2005).  
 
My  demonstration  of  decreased  mitochondrial  biogenesis  with  increasing 
inflammation  might  seem  to  contradict  evidence  that  oxidative  stress 	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stimulates mitochondrial biogenesis (Dai et al., 2014). However, it is important 
to note that my observations were based on sick animals with EAE and that 
the conditions within their cells are likely to be very different from those in 
healthy animals – it is possible that it is this very switch in the direction of 
inflammation’s relationship with mitochondria that results in the progressive 
worsening of pathology in deteriorating EAE.  
 
The suppression of mitochondrial biogenesis may be a response to increased 
inflammation and that it functions to minimize neuronal damage. As previously 
discussed, mitochondria are thought to be important mediators of oxidative 
damage  in  EAE  and  MS.  Mitochondria  are  highly  sensitive  to  damage  by 
reactive oxygen species (ROS) and are therefore especially susceptible to 
damage  within  inflammatory  lesions  in  EAE  and  MS  (Perez-Pinzon  et  al., 
2012). This poses a challenge for the production of healthy new mitochondria 
in inflammatory conditions, as mitochondrial biogenesis involves replication of 
mitochondrial DNA that are damaged, inadvertently increasing the number of 
defective  mitochondria  in  a  cell.  Since  the  accumulation  of  damaged 
mitochondria  has  been  shown  to  result  in  cumulative  oxidative  damage 
(Gottlieb  et  al.,  2011),  it  is  likely  that  the  suppression  of  mitochondrial 
biogenesis serves as a backup mechanism of mitochondrial quality control to 
limit oxidative damage caused by production of defective new mitochondria.  
 
Not  only  are  mitochondria  thought  to  perpetuate  a  vicious  cycle  of  ROS 
production and ROS-induced damage of new mitochondria, but they are also 
thought  to  exacerbate  pathology  by  causing  apoptosis  and  necrosis  of 	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neurones (Vosler et al., 2009). Mild mitochondrial membrane damage results 
in release of apoptosis inducing factor (AIF) and cytochrome c, thus initiating 
programmed cell death (Vosler et al., 2009). Severe mitochondrial damage, 
on the other hand, has been linked to Ca
2+ deregulation and cellular necrotic 
death (Vosler et al., 2009). Inhibition of the release of apoptotic factors from 
damaged  mitochondria  have  been  demonstrated  to  be  neuroprotective, 
suggesting  that  mitochondria  might  mediate  neuronal  death  in  pathological 
states  (Vosler  et  al.,  2009).  It  is  likely  that  mitochondrial  biogenesis  is 
decreased to limit the number of damaged mitochondria in a cell in order to 
prevent cellular death. In other words, it could be a mechanism to shut down 
the release of apoptosis-promoting factors in order to salvage neurological 
function.   
 
Besides  preventing  the  release  of  apoptotic  factors,  mitochondrial  quality 
control is also vital to prevent the exacerbation of inflammation.  Zhou et al. 
reported  that  the  accumulation  of  damaged,  ROS-generating  mitochondria 
result in the activation of an inflammasome, potentially worsening any existing 
inflammation (Zhou et al., 2011).  
 
Decline in mitochondrial quality control has been shown to trigger responses 
to  counteract  the  effects  of  poor  mitochondrial  quality  in  a  cell.  Studies 
conducted on yeast cells have found that the loss of mitochondrial membrane 
potential  triggers  a  pathway  called  the  retrograde  response  that,  amongst 
other  things,  results  in  the  upregulation  of  mitophagy  and  autophagy  to 	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remove  damaged  mitochondria,  thus  preventing  their  accumulation 
(Jazwinski, 2013).  
 
The  negative  relationship  between  severity  of  disease  and  mitochondrial 
biogenesis that I demonstrated in Brown Norway rats can also be explained 
from a bioenergetics point of view. Mitochondrial protein synthesis, transport 
and  assembly  are  ATP  dependent  processes  (Fox,  2012).  In  an  already 
energy-deficient  neurone,  mitochondrial  biogenesis  will  require  the 
expenditure  of  already  scarce  ATP.  In  the  severely  inflamed  CNS  of  EAE 
Brown Norway rats, neurones cannot afford to produce new mitochondria but 
instead  prioritize  cellular  respiration  in  existing  mitochondria  to  prolong 
survival. Although neurones attempt to increase their viability by blocking the 
use of ATP for mitochondrial biogenesis, this will eventually result in cell death 
as they become more and more hypoxic because existing mitochondria are 
damaged and cannot keep up with the cell’s energy demand. The same is 
true  for  the  other  arguments  put  forth  about  suppression  of  mitochondrial 
biogenesis  as  a  mechanism  to  limit  CNS  damage  –  they  all  involve  the 
assumption that the extension of lifespan is prioritized and that cells fail to 
prevent death. Failure to save neurons could underlie the progressive course 
of the disease as increasing numbers of motor neurones are lost and function 
is never recovered.  
 
Another explanation could be that mitochondrial dynamics have simply been 
derailed in EAE and that this forms part of the disease in Brown Norway rats 
both  being  caused  by  the  disease  and  further  exacerbating  it.  A  loss  of 	 ﾠ 82	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mitochondrial  regulation  in  disease  is  not  unprecedented:  mitochondrial 
defects  have  long  been  implicated  in  a  range  of  CNS  diseases  such  as 
Leber’s hereditary optic nerve atrophy (LHON), maternally inherited Leigh’s 
syndrome  (MILS)  and  Pearson  syndrome  (Kalman,  2006).  Other 
neurodegenerative diseases with close links to EAE have also been reported 
to be caused by a variety of mitochondrial defects (Beal, 2005; Calkins and 
Reddy, 2011b).  
 
Clustering of mitochondria towards the axon hillock: 
The observation that mitochondria cluster towards the axon hillock of motor 
neurones in inflamed regions of the spinal cord of the LPS injected animals 
suggested that there seems to be a localized site of mitochondrial biogenesis 
in these neurones. This peculiar distribution was only observed in animals 
examined at the peak of inflammation (48-72 hours after LPS) and which also 
showed  increased  mitochondrial  biogenesis  as  evaluated  by  the  BrdU 
method.  Although  a  few  cells  in  the  EAE  studies  showed  this  type  of 
distribution it was not as pronounced and wide spread as the LPS studies. 
This is perhaps due to the precise nature of the LPS injection model where all 
cells  are  experiencing  a  similar  tissue  environment  compared  with  the 
stochastic  and  relatively  unpredictable  nature  of  the  neuroinflammatory 
pathology in EAE. This observation along with the localization of BrdU signal 
to the cell body in previous experiments led to the hypothesis that perhaps 
mitochondrial biogenesis occurs only in the cell body of long neurones. This 
observation was investigated further, and is discussed in Chapter 4.  
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Chapter 4: Cell Biology of 
mitochondrial biogenesis 
Introduction 
Mitochondria are key to the survival of neurones (Nicholls, 2002), however, 
depending on the activity of the network and the biochemical identity of  the 
neurones the energy needs can vary greatly in their demand of energy not 
just  across  types  of  cells  but  also  different  compartments  within  a  long 
neurone (Hollenbeck and Saxton, 2005). Certain areas of long neurones have 
higher  need  for  energy  such  as  nodes  of  Ranvier  (Berthold  et  al.,  1993; 
Waxman and Ritchie, 1993), myelination boundaries (Bristow et al., 2002), 
active synapses or tracts (Bindokas et al., 1998; Kageyama and Wong-Riley, 
1982;  Wong-Riley  and  Welt,  1980)  and  active  growth  cones  or  axonal 
branches (Morris and Hollenbeck, 1993; Ruthel and Hollenbeck, 2003) and 
these  regions  accumulate  mitochondria.  Neurones  traffic  mitochondria  all 
across distal regions of the cells and continuously carry out fission and fusion 
to deal with changing energy demands in the cells.  
 
Due  to  the  cyclical  nature  of  mitochondrial  lifecycle  along  with  the 
redistribution  the  neurons  must  also  regulate  the  process  of  organelle 
biogenesis to replace damaged mitochondria. Most mitochondrial proteins are 
encoded in the nuclear genome that presents a challenge for carrying out 
biogenesis in all corners of a large cell such as a motor neurone. In previous 	 ﾠ 85	 ﾠ
studies  in  PC-12  cells  mtDNA  replication  has  been  mainly  detected  in  the 
perinuclear region (Davis and Clayton, 1996). However, more recently this 
has been observed to occur in axons of chick sensory neurones in culture 
(Amiri  and  Hollenbeck,  2008).  Components  of  the  mitochondrial  replication 
apparatus  have  been  found  outside  of  the  perinuclear  region  in  both  non-
neuronal cells (Falkenberg et al., 2002; Larsson et al., 1994; Tiranti et al., 
1997)  and  neuronal  cells  (Magnusson  et  al.,  2003),  which  suggests  that 
biogenesis could occur in the distal regions of neurons.  
 
In my initial observations of BrdU signal in vivo in spinal motor neurones we 
found the signal strongly localized to the perinuclear mitochondrial pool. This, 
along with the observation that when stained with antibodies against TFAM 
there seemed to appear a clustering of mitochondrial DNA in the axon hillock 
of motor neurones, which showed higher levels of mitochondrial biogenesis 
following inflammation (Chapter 3) led us to ask whether these cells primarily 
perform mitochondrial biogenesis only in the cell body. Here we have tested 
the hypothesis that in vivo neuronal mitochondrial biogenesis largely occurs 
only in cell bodies of neurons. We have used a sensitive method of BrdU 
detection  to  examine  mtDNA  in  motor  neurone  cell  bodies  from  the  grey 
matter of the spinal cord and then examined the signal in axons, which are 
contained in the sciatic nerve, after delivering BrdU systemically. The picture 
that emerged suggested that biogenesis is largely conducted in the soma of 
the neurones and these newly formed particles are then trafficked along the 
length of the axons. We have tried to corroborate the speed of movement of 
mitochondria using an alternate labelling method using the potentiometric dye 	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MitoTracker® Red. Finally we show that the process of somatic mitochondrial 
biogenesis is enhanced following the initiation of high demand of energy by 
electrical stimulation. 
Methods 
Part 1   
In vivo experiment – somatic nursery: 
For  this  first  study,  we  injected  two  doses  of  BrdU  at  100  mg/kg  5  ml/kg 
intraperitoneally (systemic administration), 2 hours apart, into adult C57/Bl6 
mice  weighing  between  25-30  g.  Cohorts  of  animals  were  sacrificed  at 
different times after the injection by cardiac perfusion. Animals were kept for 
up to 21 days after injection and sacrificed at different time points (Figure 1). 
Tissue  from  the  animals  was  stored  overnight  in  4%  PFA  and  then 
cryopreserved  in  30%  sucrose  before  being  processed  for 
immunohistochemistry.  
 	 ﾠ 87	 ﾠ
	 ﾠ 
Figure  1:Timeline  of  pulse  chase  experiment  to  determine  the  location  of 
mitochondrial  DNA  replication.  The  first  experiment  was  conducted  with 
sacrificing animals at different days after the injection of BrdU, and the second 
experiment was conducted where animals were sacrificed at different hours 
after the second injection of BrdU.  
 
Immunohistochemistry: 
Immunohistochemistry  was  performed  as  described  (Chapter  2).  Sections 
from the region of the spinal cord containing the motor neurons of the sciatic 
nerve were used for ‘cell body analysis’, and sections from the first centimeter 
of the sciatic nerve were used to analyze ‘axons’. Both kinds of sections were 
stained for VDAC-1 in red (Alexa Fluor 546) and BrdU in green (Alexa Fluor 
488).  
 
Imaging and Analysis: 
Fluorescent  labeling  was  observed  through  a  LSM  5  Pascal  confocal 
microscope (Zeiss, Oberkochen, Germany) and images were recorded with 
the  Pascal  software  (Zeiss).  All  image  analysis  was  done  using  Image  J 	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(NCBI, USA) and corresponding plug-ins. All staining was checked for non-
specific  antibody  labelling  using  control  slides  without  primary  antibody,  or 
without secondary antibody, or without fluorescently labeled streptavidin.  
 
Images  of  the  cell  bodies  of  motor  neurones  were  analysed  in  3D  stacks 
collected  with  1  μm  thick  optical  sections  and  analysed  using  3D  Object 
counter using FIJI (ImageJ). The analysis was represented as the percentage 
particles  of  VDAC-1,  which  also  showed  positive  staining  for  BrdU.  Slides 
from every animal were analysed using the same settings normalized against 
a positive control section from the intestinal region. Laser power, aperture of 
Iris and PMT gain were kept consistent for the collection of images across the 
whole experiment. Threshold used for the analysis of particles was also kept 
consistent.  
 
A similar analysis was performed for the axons of the cells. The analysis on 
nerves was not performed using 3D because of the frailty of the tissue. 2D 
particle count was performed on a ‘maximum intensity’ Z projection of the 
section imaged using 1μm optical sections. This method may have resulted 
in the loss of some signal due to missing particles in z-planes other than the 
one  captured.  One  way  of  showing  qualitatively  that  the  BrdU  reached  all 
parts  of  the  body  is  the  mitotic  signal  which,  occurs  in  the  nuclei  of 
proliferating glia in the CNS as well as the PNS and appears as solid green 
blots in all samples.  
Time points were generated such that every time group had 5 animals.  
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Part 2 
Intraspinal LPS injection of MitoTracker® Red: 
In  order  to  corroborate  the  potential  speed  of  movement  of  newly  formed 
mitochondria  which  was  suggested  in  the  BrdU  experiment,  we  used  a 
second method of labelling mitochondria in the somatic pool. We used the 
potentiometric dye MitoTracker® Red which, when loaded into mitochondria, 
sticks to membrane and can be post-fixed with PFA, and imaged.  
Adult  (250-350  g)  Sprague  Dawley  (SD)  rats  were  anaesthetised  with  2% 
isoflurane (Merail, Harlow, UK) in 100% oxygen and the site of operation was 
shaved and sterilised with iodine. Subsequently, animals received a quarter 
laminectomy of the 13
th lumbar (T13-L1) vertebral. Once the spinal cord was 
exposed, a small incision was made in the dura and pia, and 2 injections of 
0.5  µl  of  MitoTracker®  Red  0.5  mM  (Life  technologies  M-7512)  were 
performed at 700 μm distance from the dorsal vein and a depth of 1100 μm. 
For injections, a glass drawn micropipette held in a micromanipulator with a 
trajectory of 24 degrees to the vertical was used. Injection sites were marked 
with a small amount of sterile charcoal. Control animals were injected with 
sterile PBS. Following this the animals were left to recover from surgery and 
then sacrificed by cardiac perfusion at 4 (n=3) and 8 (n=3) hours after the time 
of injection.  
Tissue preparation for imaging: 
After cardiac perfusion the tissue was placed overnight in a 4% solution of 
PFA and then cryopreserved in 30% sucrose. Tissue blocks were made from 
regions  of  the  spinal  cord  with  the  sciatic  motor  neurones  and  the  sciatic 
nerve  was  collected  and  cut  into  1  cm  lengths  before  being  blocked  for 
longitudinal sectioning. Every section of the nerve cut using the cryostat was 	 ﾠ 90	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collected. A control piece of tissue from the spinal cord 0.5 cm away from the 
site of injection was also collected in order to determine whether the dye had 
reached that far in the tissue by simple diffusion. Sections from this region did 
not show any fluorescence signal. The resulting tissue was embedded and 
sectioned using a cryostat at a thickness of 12 μm. The tissue was then left 
to  dry  and  directly  mounted  with  Fluoromount  Aqueous  Mounting  medium 
(Sigma Aldrich F-4680).  
Imaging and analysis: 
Images  were  acquired  using  a  LSM  5  Pascal  confocal  microscope  (Zeiss, 
Oberkochen, Germany) and images were recorded with the Pascal software 
(Zeiss). The control animal, which was injected with PBS, did not show any 
significant  fluorescence  signal  in  sections  from  the  spinal  cord  or  sciatic 
nerve. Motor neurone cell bodies were analysed using an intensity threshold 
and  total  content  of  positive  particles  of  MitoTracker®  Red  fluorescence 
containing  within  the  volume  of  a  cell.  The  sciatic  nerve  sections  were 
analysed for the area occupied by fluorescence intensity above the threshold 
normalised for the area of the section. The data were then averaged across 
the three animals. An ANOVA test was performed for statistical testing.  
Part 3 
Electrical Stimulation- in vivo experiment: 
Electrical  stimulation  was  performed  in  mice  adult  C57/Bl6  mice  weighing 
between 25-30 g. Animals were given an initial dose of BrdU (100 mg / kg; 5 
ml  /  kg)  in  saline  intraperitoneally.  After  105  minutes,  the  animals  were 
anaesthetised and prepared for surgery. The animals were anaesthetized with 
isoflurane (5%) and maintained with 1.5%. The sciatic nerves were surgically 	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exposed on both sides and a Teflon tape was placed under a section of the 
nerve for electrical isolation as photographed in Figure 2. The preparation was 
soaked in mineral oil to provide electrical isolation from surrounding tissue 
and to prevent drying (Figure 2). Electrical stimulation was provided using a 
constant voltage isolated stimulator (Digitimer, UK). Paired electrodes were 
placed cupping the sciatic nerve around the hip area. The right side was given 
stimuli of amplitude 5 V (supramaximal), while the left (control) side was kept 
at 0 V. Stimuli (0.1ms duration) were delivered at 100 Hz for 2 hours.  At the 
start  of  stimulation  a  second  dose  of  BrdU  was  administered  of  the  same 
dose. After checking that the stimulation was effective, the sciatic nerves were 
crushed distally to avoid tetanic stimulation of the muscles. At the end of 2-
hour protocol, animals were sacrificed by cardiac perfusion.  
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Figure 2: Photograph of C57Bl/6 mouse with exposed sciatic nerve prep. Both 
sides of the nerve are exposed, bathed in mineral oil isolated with Teflon tape 
and stimulated using custom made silver wire electrode assembly. The right 
hand side was stimulated at 100 Hz and 5 V and the left at 100 Hz and 0 V as 
a control.  
 
Tissue preparation for imaging: 
After cardiac perfusion the tissue was placed overnight in a 4% solution of 
PFA and then cryopreserved in 30% sucrose. Tissue blocks were made from 
regions  of  the  spinal  cord  with  the  sciatic  motor  neurones  and  also  1  cm 
above from the thoracic region of the spinal cord as a control. Since the entire 
electrical  pathway  was  stimulated  in  this  protocol  dorsal  root  ganglia  were 
also collected from these animals. The resulting tissue was embedded and 
sectioned using a cryostat at a thickness of 12 μm. The tissue was then left 	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to  dry  and  then  directly  mounted  with  Fluoromount  Aqueous  Mounting 
medium (Sigma Aldrich F-4680).  
 
Immunohistochemistry: 
BrdU  was  detected  with  fluorescence  immunohistochemistry. 
Immunohistochemistry  was  performed  as  described  before  (Chapter  2). 
Briefly,  the  sections  were  incubated  with  primary  antibodies:  rat  anti-BrdU 
(AbD  Serotec,  MCA2060)  1:200  dilution  in  PBS  and  rabbit  anti-VDAC1 
(voltage dependent anion channel 1, Abcam) 1:600 dilution, overnight in the 
fridge. The following day, sections were washed 3 times for 15 minutes with 
PBS and once with PBS and 0.3% Tween. A secondary antibody was then 
applied: biotinylated goat anti-rat IgG mouse absorbed (Vector Labs) 1:200, 
and Alexa Fluor 546 conjugated goat anti- rabbit IgG (Invitrogen) 1:200 for 2 
hours at room temperature. The slides were washed 3 times for 15 minutes 
with PBS and 0.3% Tween, after which the BrdU signal was amplified using 
Alexa  Fluor  488  streptavidin  (Invitrogen)  1:200  for  90  minutes  at  room 
temperature. The last 3 washes for 15 minutes with PBS were performed and 
then the slides were mounted with Fluoromount Aqueous Mounting Medium 
(Sigma). Control animals (no BrdU) for the electrical stimulation experiment 
were labelled with mitochondrial transcription marker- TFAM (transcriptional 
factor A, mitochondrial). All the previous steps were the same except using 
Target Retrieval Solution (Dako) instead of HCl treatment.  
1.  Primary  antibodies:  Rabbit  anti-TFAM  antibody  (Sigma)  1:2000  and 
NeuN (Neuronal Nuclei, Mouse monoclonal; Millipore) 1:500 dilution. 
2.  Secondary  antibodies:  Goat  anti-rabbit  biotinylated  mouse  absorbed 	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(Vector Labs);  goat anti-mouse IgG conjugated with Alexa Fluor 546 
(Invitrogen).    TFAM  signal  was  amplified  using  Alexa  Fluor  488 
streptavidin (Invitrogen). All dilutions were at 1:200. 
 
Image acquisition 
All fluorescently labelled sections were imaged using a Zeiss LSM 5 Pascal 
confocal  microscope  (Zeiss,  Oberkochen,  Germany)  at  63x  oil  immersion 
magnification. Alexa Fluor 488 and Alexa Fluor 546 were excited with a 488-
nm argon laser and 543-nm HeNe laser, respectively. The spinal cord and 
dorsal root ganglion sections were imaged using a Z-stack mode producing 
10-12  slices  at  1μm  thick.  All  the  nerve  sections  and  ventral/dorsal  roots 
were  imaged  using  a  Tile  mode  (X=5;  Y=2).  Mitochondria  labelled  with 
BrdU/TFAM and VDAC-1 were assessed with two different channels. All the 
settings  were  kept  constant  throughout  imaging,  to  facilitate  direct 
comparisons. 
 
Image Processing and Analysis: 
Images were recorded with Pascal software (Zeiss) and analysed with Image 
J  software  (NCBI,  USA).  Each  cell  of  interest  was  isolated  and  analysed 
individually for BrdU content in BrdU positive mitochondria. A threshold for 
fluorescence intensity was set manually and kept the same throughout the 
analysis. The correct threshold settings helped to exclude from the count the 
BrdU positive nuclear DNA and only counted the BrdU positive mitochondrial 
DNA.  A  3D  object-counter  plugin  was  used  to  count  the  number  of 
mitochondria labelled with BrdU. The plugin also provided us with read outs of 
the volume of each particle and the maximum particle fluorescence intensity 	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of the cell. Then, for each cell of interest, a Z project plug in was applied, and 
the percentage of BrdU positive particles was calculated per particle count for 
VDAC-1.  This  method  gives  a  read  out  of  the  percentage  of  mitochondria 
undergoing DNA replication.  
 
Due to the high concentration of mitochondria in sensory neurones from the 
dorsal  root  ganglion,  only  a  BrdU  content  analysis  was  possible  in  these 
sections.  Threshold  fluorescence  intensity  was  used  to  define  positive 
labelling and then the content was normalised to the size of the cell body. 
Statistical analysis 
Changes  in  pattern  of  mitochondrial  biogenesis  in  short-time  series 
experiments  were  analysed  using  GraphPad  Prism6  software,  a  one-  way 
ANOVA  analysis  (p<0.5).  The  electrical  stimulation  experiments  were 
assessed  using  the  unpaired  two-tailed  Student’s  t  test  (p<0.05).  The 
stimulated (right) side was compared to the control (left) side for significant 
change in mitochondrial biogenesis. Raw data are plotted as dot plots to show 
the population distribution. 
Results 
Somatic mitochondrial nursery 
	 ﾠ
All observtaions of the BrdU signal from spinal cord motor neurones were 
performed in C57Bl/6 mice. Images of at least 80 cell bodies were acquired as 
z-stacks  were  analysed  for  percentage  of  VDAC-1  positive  particles 
containing a mtDNA replication signal marked with BrdU as represented in 
Figure  3.  This  signal  was  used  as  a  surrogate  marker  for  mitochondrial 	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biogenesis.  All  sections  analysed  showed  strong  labelling  for  BrdU  in  the 
proliferating nuclei of mitotic cells such as glia. This suggests in terms of the 
distribution  of  BrdU  in  when  administered  systemically,  is  available  for 
inclusion into replicating DNA.  
 
 
Figure 3: Representative confocal images of sections through individual motor 
neurone  cell  bodies  of  mouse  spinal  cord  showing  different  amounts  of 
mitochondrial biogenesis or mitochondrial DNA replication as measured with 
VDAC-1 (red) and BrdU (green). These cells were analysed in 3D via optical 
stacks to accurately measure the per cent of VDAC-1 positive particles also 
containing BrdU, where all staining was done together and all images were 
analysed  using  the  same  digital  settings  of  brightness  and  contrast  and 
threshold of brightness. 
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Figure  4:  Representative  confocal  images  of  sections  through  individual 
axons  from  mouse  sciatic  nerve  sections  from  the  first  centimetre  of  the 
sciatic nerve. These nerve axons were analysed in 3D via optical stacks to 
accurately measure the per cent of VDAC-1 positive particles also containing 
BrdU, where all staining was done together and all images were analysed 	 ﾠ 97	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using the same digital settings of brightness and contrast and threshold of 
brightness. 
 
The pulse and chase experiments were analysed over 5 animals at each time 
point.  The averaged percentage points are represented in Figures 5 and 6. 
 
In  the  early  time  points  the  signal  of  BrdU  in  the  somatic  (cell  body) 
mitochondrial  rises;  reaching  a  peak  at  4  hours.  This  time  represents  the 
pharmacokinetic  peak  of  BrdU.  Curiously  however,  the  mitochondrial  BrdU 
signal seemed to be localized to cell bodies of neurones in the grey matter of 
the spinal cord in the first 6-8 hours, while, the mitotic BrdU signal seems to 
appear in all the tissue sections, suggesting that only the mitochondria in the 
cell body are carrying out DNA replication. 
 
 The  co-localization  of  VDAC-1  and  BrdU  in  the  axonal  sections  from  the 
sciatic nerve was observed only in the animals sacrificed 6 or more hours 
after the injection of BrdU. This suggests that most of the mtDNA replication 
occurs in the mitochondria contained within the soma of motor neurones. The 
appearance of BrdU in axonal mitochondrial after 6 hours could be explained 
as an effect of newly formed DNA particles having moved into the axons via a 
combination  of  processes  i.e.  trafficking,  fission  and  fusion.  The  speed  of 
movement  of  these  potentially  new  mitochondria  was  calculated  using  the 
distance and the amount of time after the second injection of BrdU and it was 
determined to be in the range of 0.28 – 0.46 μm/s. This evidence along with 
the observation of clustering of mitochondrial particles around the axon hillock 
(Chapter 3) suggests the presence of a somatic mitochondrial nursery.  	 ﾠ 98	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Figure 5: This graph shows the BrdU content in each cell across each animal 
at each time point. There is a sharp rise of BrdU content after 4 hours, which 
is representative of the pharmacodynamic peak of BrdU distribution. The fall 
after 2 days perhaps represents a distribution of newly formed mtDNA or a 
breakdown of the BrdU signal. 
 
 
Figure  6:  Graph showing the BrdU content in sciatic nerve axons at each 
animal across each time point. There is a sharp rise of BrdU content after 8 
hours,  which  is  representative  of  the  newly  formed  mitochondrial  DNA 
contained within mitochondria moving down the axon.  
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Figure 7: When comparing the mitochondrial BrdU in cell bodies and in axons 
there is a statistically significant difference at 15 min, 2 hours, 4 hours and 6 
hours  between  the  two  compartments  of  the  cell.  A  two-way  ANOVA  was 
performed  to  compare  the  biogenesis  signal  between  soma  and  axon 
(p<0.0001).  This  represents  a  lag  of  6-8  hours,  which  suggests  that  most 
mtDNA  replication  occurs  in  the  cell  bodies  and  travels  down  via  axonal 
transport. The velocity of movement is 0.28 – 0.46 μm/s 
 
MitoTracker® Red  
In  order  to  corroborate  the  speed  of  movement  down  the  axon  using  an 
alternate method of labelling, Mitotracker Red was used as a dye to label 
mitochondria  in  vivo  in  Sprague  Dawley  adult  rats  and  examined  in  post 
mortem tissue. The MitoTracker® Red was injected close to the ventral horn 
where the motor neuron cell bodies are located. The signal was picked up 
nicely into the mitochondrial in the motor neurone soma as shown in Figures 
8a and 8b. The sections from a region 0.5 cm away from the site of injection 
showed  no  fluorescence  signal,  suggesting  that  by  sheer  diffusion  the 
concentration of the dye had not been enough to stain mitochondria in that 	 ﾠ 100	 ﾠ
region. This suggests that it would be unlikely for enough MitoTracker® Red 
reaching the axon by simple diffusion. The signal, which appeared in different 
sections of the sciatic nerve after 4 hours and 8 hours of after injection of 
MitoTracker® Red, is shown in Figures 8 c, d and e. The signal was then 
averaged  over  three  animals  at  each  time  point  and  the  analysis  is 
represented in Figure 9.  
 
We believe that the appearance of these dye containing particles in the axons 
represents mitochondria which picked up dye from the somatic region while in 
the somatic region of the motor neurone, and then were trafficked along the 
axon towards the peripheral regions of the nerve. From these observations we 
calculated the speed of movement of these particles and was found to be 
between 0.35 and 1.05 μm / second.  
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Figure 8: Confocal images of  sections spinal cord from adult rat and sciatic 
nerve after intraspinal injection of MitoTracker® red. (A) is a composite tiled 
image showing the ventral horn region near the injection site, 4 hours after 
injection. Dye is clearly collected in cell bodies and projections neat the site. 
(B) is a high magnification image of one motor neuron with clear punctate 
labelling of mitochondria with the dye. (C) is a section of the nerve 1 cm from 
the spinal cord, (D) is 2 cm away and (E) is 3 cm away, 8 hours after injection 
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Figure 9: Analysis of MitoTracker® red labelled mitochondrial in 1, 2, and 3 
cm  away  from  the  spinal  cord  4  hours  (blue)  and  8  hours  (red)  after  the 
surgery. Virtually no signal appears in sciatic nerve axons after injection of 
MitoTracker®  Red  into  the  ventral  horn  grey  matter  until  8  hours  after 
injection. The calculated speed of movement of mitochondria is 0.35 – 1.04 
µm/s 
 
Mitochondrial biogenesis responds to electrical stimulation 
The observation of a somatic nursery for mitochondrial biogenesis along with 
the appearance of clustering of mitochondria towards the axon hillock, and the 
increase  of  mitochondrial  DNA  replication,  were  stepping  stones  towards 
testing  whether  the  mitochondrial  biogenesis  is  initiated  in  cell  bodies  of 
neurones  following  a  period  of  high  activity  as  simulated  by  external 
stimulation of the sciatic nerve. Mice which had not been administered BrdU 
as  a  control,  were  sectioned  and  stained  using  antibodies  against 
mitochondrial  transcription  factor  A  (TFAM),  there  was  a  clear  increase  in 
signal unilaterally following electrical stimulation (Figure 10).  
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Figure 10: Staining of spinal cord tissue from adult mice to visualise TFAM 
(green) and NeuN (red). The right side of the animal (upper panel) shows 
enhanced TFAM staining in neurons following 2 hours of electrical stimulation. 
 
Upon  observation  of  mitochondrial  biogenesis  signal  as  measured  using 
previously  described  methods  (Appendix)  there  was  a  clear  unilateral 
increase in biogenesis following stimulation of the sciatic nerve on one side, in 
motor  neuron  cell  bodies  (Figures  11  a  and  b).  Furthermore,  the  a  higher 
signal was observed in the sensory neurons from the right (stimulated) dorsal 
root ganglion than that in sensory neurones from the left side (Figures 11 c 
and d). Also when motor neurones from the right (stimulated) were compared 
with a section of the spinal cord away from the site of stimulation (Figures 11 
e and f), it was observed that the site of stimulation contained cell bodies with 	 ﾠ 104	 ﾠ
a higher biogenesis signal than the ones in a region of the spinal cord which 
had received no external stimulation.  
 
Figure 11: Confocal images comparing the right and left side neurones after 
unilateral electrical stimulation in mice to increase energy demand labelled for 
BrdU content (Green). (A) is an image of the sham side motor neurones. (B) 
is  a neurone from the stimulated side. (C) is an image of the dorsal root 
gangion from sham side and (D) is from the stimulated side. (E) is an image of 
a motor neuron from the same side as the electrical stimulation but from the 
thoracic  region  of  the  spinal  cord  which  does  not  containing  cell  bodies 
corresponding with the sciatic nerve. (F) is a motor neuron from the lumbar 
region where the sciatic nerve emerges.  
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Upon averaging the mitochondrial biogenesis signal from cell bodies across 5 
animals,  it  was  observed  that  the  signal  was  significantly  higher  on  the 
stimulated side than the control side as tested with a paired t-Test in figures 
12 and 13 for motor neurones as well as sensory neurones. Due to the high 
amount of signal observed in sensory neurones it was not possible to perform 
the  previously  described  mitochondrial  biogenesis  signal  of  percentage  of 
VDAC-1  particles  positive  for  BrdU.  Instead,  the  simple  content  of  BrdU 
normalised for the size of cell and set threshold for fluorescence intensity was 
evaluated. Also as represented in Figure 14 the motor neurone cell bodies 
from the region of the spinal cord 1 cm away from the site of stimulation were 
found to have far less BrdU signal than the motor neurone cell bodies from 
the  stimulated  region  of  the  spinal  cord.  There  is  a  fair  amount  of  spread 
observed (Figures 12a, 13a and 14a) which is representative of the diversity 
of motor neurones, both in size, type and activity.  
 
 
Figure 12: Left graph shows the spread of BrdU signal across different sides 
of the spinal cord, stimulated (red) and sham (blue) in one animal. Right graph 
shows  averaged  over  n=5)  the  result  is  found  to  be  statistically  significant 
(p=0.00037) 
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Figure  13:  Left  graph  shows  the  spread  of  BrdU  signal  across  sensory 
neurones  of  different  sided  dorsal  root  ganglia  stimulated  (red)  and  sham 
(blue)  in  one  animal.  When  averaged  over  (n=5)  the  result  is  found  to  be 
statistically significant (p=0.000297) 
 
 
Figure 14: Left graph shows the spread of BrdU signal in motor neurones of 
the  thoracic  region  and  lumbar  region  stimulated  (red)  and  away  from 
stimulated (blue) in one animal. When averaged over (n=5) the result is found 
to be statistically significant (p=0.00037) 
 
We suggest that these data demonstrate the presence of a somatic nursery 
for mitochondrial biogenesis, which increases its rate of growth in response to 
increases in energy demand, such as resulting from electrical stimulation or in 
response to damage as in the case of neuroinflammation. 
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Discussion: 
Mitochondrial biogenesis in the soma: 
Neurons are large cells that rely on mitochondrial function (Nicholls, 2002) 
and thus the rapid and versatile distribution of mitochondrial activity over time 
and space is critical (Hollenbeck and Saxton, 2005). They are also typically 
long-lived cells in which mitochondria must dilute the products of their error-
prone DNA replication (Schapira, 1993) by fission and fusion (Chan, 2006; 
Chang  and  Reynolds,  2006;  Hoppins  et  al.,  2007;  Ono  et  al.,  2001),  and 
renew themselves through biogenesis. The dying-back peripheral neuropathy 
observed in AIDS patients (Raff et al., 2002) treated with nucleoside inhibitors 
of mtDNA replication (Dubinsky et al., 1989; Pardo et al., 2001; Raff et al., 
2002) emphasizes the importance of mitochondrial biogenesis for the integrity 
of  the  axon.  Other  deficiencies  in  mitochondrial  biogenesis,  such  as  those 
associated with ageing, affect neurons more than other cell types (Miquel, 
1991)  and  probably  underlie  neurodegenerative  disorders  (Linnane  et  al., 
1989).  But  where  in  this  large  and  asymmetric  cell  does  mitochondrial 
biogenesis occur? Because most mitochondrial proteins are encoded in the 
nuclear genome (Neupert, 1997) it has been suggested that all mitochondrial 
biogenesis occurs in the cell body, close to the nucleus (Davis and Clayton, 
1996).  A  body  of  recent  work  revealing  components  of  the  machinery  for 
mitochondrial  replication  within  axons  has  refocused  our  attention  on  this 
issue,  as  has  the  detection  of  mtDNA  replication  in  neurites  of  SH-SY5Y 
neuroblastoma  cells  (Magnusson  et  al.,  2003).  More  recent  studies  have 
suggested that mtDNA replicates in axons, as well as the cell body, in cultures 
chick sensory neurones (Amiri and Hollenbeck, 2008)  	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I have addressed the location of neuronal mitochondrial biogenesis in vivo in 
mammalian  neurones  that  have  a  particular  vulnerability  to  mitochondrial 
dysfunction – motor neurones. I find that the majority of mitochondrial DNA 
replication occurs in the soma of these neurones. It may be postulated that 
there is a nursery of mitochondria located close to the perinuclear region of 
motor  neurones,  which  gets  activated  by  a  need  for  new  mitochondrial 
production.  This  provides  quick  access  to  the  nuclear  machinery,  which  is 
necessary  for  the  transcription  of  mitochondrial  genes,  and  perhaps  also 
isolates  the  ‘mother’  mitochondria  from  mitochondria  damaged  in  the 
peripheral parts of the neurites. This also presents a new challenge. It maybe 
speculated that if there is high oxidative stress near the neuronal cell body 
this may ‘poison’ the somatic nursery and perhaps manifest in mitochondrial 
pathology  all  through  the  cell  more  quickly  than  local  changes  in  the 
periphery. With support for the existence of clonal expansion of mitochondrial 
damage  in  various  neurodegenerative  diseases  and  tissues  it  may  be 
speculated that the poisoning of mitochondrial nursery which is triggered by a 
variety  of  pathologies  such  as  a  blood  barrier  breakdown,  genetic 
susceptibility, hypoxia could potentially knock out types of cells where the cell 
bodies are exposed to the oxidative stress. 
Distribution of newly formed mitochondria: 
Our understanding of the neuron as a dynamic metabolic system depends 
critically upon where in the cell mitochondrial biogenesis occurs. If it is limited 
to  the  cell  body,  then  axonal  mitochondria  are  purely  visitors  in  the  axon 
whose lifetime prior to turnover will barely equal the time necessary to reach 
the distal ends of long peripheral axons. In this case, axons could respond to 	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changes  in  local  need  for  mitochondrial  function  only  by  redistributing  or 
regulating the activity of mitochondria that are already undergoing transport 
through  the  axon.  This  then  presents  a  further  importance  on  the  efficient 
transport of mitochondria to the peripheral regions of the neurone. The speed 
of movement we estimate using our two methods BrdU (0.28 – 0.46 μm/s) 
and  MitoTracker®  Red  (0.35  and  1.05  μm/s)  are  both  comparable.  The 
MitoTracker® Red studies are carried out in SD rats while the BrdU method 
was carried out in C57 mice. Furthermore, the BrdU only measures the speed 
of movement of ‘new’ mtDNA and the method will not detect any signal if the 
BrdU  has  been  diluted  via  the  process  of  fusion  and  fission  below  the 
technical  limit  of  immunohistochemistry.  These  experimental  caveats  may 
account for the difference in the estimated speed of movement. However,  our 
estimates  are  not  very  different  from  previously  observed  speed  of 
mitochondrial movement estimated by in vivo imaging of moving mitochondria 
in the saphenous nerve of mice (0.3-0.7 μm/s) (Sajic et al., 2013)   
 
Mitochondrial biogenesis response to electrical stimulation: 
I  observed  a  physiological  relationship  between  impulse  activity  and 
mitochondrial  biogenesis  in  vivo.  Earlier  studies  conducted  in  vivo  have 
reported  induced  activity  was  associated  with  a  increase  in  mitochondrial 
transport,  and  an  accumulation  of  mitochondrial  (Sajic  et  al.,  2013).  In 
conjunction to this change I observe that at high frequency stimulation we a 
unilateral increase in mitochondrial biogenesis on the side of stimulation in 
both the motor and sensory neurones occurred. Along with the importance of 
mitochondrial  transport  in  these  neurones  this  study  emphasizes  the 	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importance of mitochondrial turnover. It has been observed in the past that 
exercise induces mitochondrial biogenesis in skeletal muscle cells (Holloszy, 
2011).  This  paradigm  of  electrical  stimulation  suggests  a  similar  type  of 
demand-generated increase of biogenesis in the neurones. This maybe one 
of  the  ways  the  CNS  is  able  to  maintain  health  via  the  balance  of 
mitochondrial biogenesis and mitophagy following periods of high activity 
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Chapter 5: Hot-spots of 
mitochondrial biogenesis 
Introduction 
The brain is a highly metabolic tissue, and neurons in the central nervous 
system  have  an  intense  demand  for  mitochondria  (Wang  et  al.,  2009). 
Mitochondria  provide  most  of  the  ATP  for  cellular  reactions  in  neurones 
(Herrero-Mendez et al., 2009). ATP production in mitochondria is coupled to 
an  electron  transport  system  in  which  the  passage  of  electrons  down  the 
various electron carriers is associated with the transport of protons from the 
matrix into the inter-membrane space. The majority of these protons reenter 
the mitochondrial matrix by the ATP synthase, thereby generating ATP.  
 
Studies of aging brain mitochondria consistently report reductions of complex 
I activity, complex IV activity, and increased ROS production (Navarro and 
Boveris,  2007b).  Other  age-related  mitochondrial  changes  include  reduced 
membrane potential and increased size. Mitochondrial DNA mutations may 
contribute to age-related mitochondrial decline. MtDNA deletions accumulate 
with age in many tissues, especially brain preferentially in certain neuronal 
niches (Corral-Debrinski et al., 1992).  
Mitochondria  are  altered  in  the  brains  of  persons  with  certain 
neurodegenerative diseases (Navarro and Boveris, 2007a; Swerdlow, 2007b). 
There  are  activity  reductions  of  complex  I  in  Parkinson's  disease  (PD), 	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cytochrome  oxidase  in  Alzheimer's  disease  (AD),  and  multiple  electron 
transport chain (ETC) enzymes in Huntington's disease (HD). Mitochondrial 
dysfunction  occurs  in  amyotrophic  lateral  sclerosis  (ALS)  and  progressive 
supranuclear  palsy.  Leber's  hereditary  optic  neuropathy  (LHON),  a  focal 
degeneration of the optic nerves, arises from mutations in mtDNA-encoded 
complex I genes and is associated with complex I dysfunction. 
 
These observations were crucial in driving the hypothesis that perhaps there 
is  a  constitutive  activation  of  mitochondrial  biogenesis  in  certain  neuronal 
niches  due  to  certain  factors.  These  factors  include  energy  metabolism, 
neurotransmitter identity, size of cell, inherent electrical activity, myelination 
profile  or  need  for  mitochondrial  repair  and  might  require  an  elevated 
mitochondrial biogenesis. We have used the BrdU mitochondrial biogenesis 
probe to blindly identify region of the CNS and PNS, which exhibited a high 
turnover  of  mitochondrial  DNA.  Notably,  the  regions  of  high  turnover  we 
identified match neuronal niches that are susceptible to mitochondrial damage 
and primary mitochondrial disease.  
  
Methods	 ﾠ
In	 ﾠvivo	 ﾠexperiment:	 ﾠ
Two  doses  of  BrdU  were  injected  at  100  mg/kg  intraperitoneally  (systemic 
administration),  2  hours  apart,  into  adult  Sprague  Dawley  rats  weighing 
between 200-250 g. Animals were sacrificed at 24 hours after the injection by 
cardiac  perfusion.  Several  sets  of  tissue  including  brain,  spinal  cord, 
peripheral  nerves,  dorsal  root  ganglia  and  eyes  were  harvested  from  the 	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animals  and  stored  overnight  in  4%  PFA  and  then  cryopreserved  in  30% 
sucrose before being processed for immunohistochemistry. 
Immunohistochemistry: 
Immunohistochemistry was performed as previously described in Chapter 2. 
Additionally, antibody to the dopaminergic cell marker tyrosine hydroxylase 
(TH)  Pel-Freez (P40101-0), rabbit polyclonal) was used at dilution of 1:250 to 
detect the identity of dopaminergic cells in the ventral tegmental area and 
substantia nigra regions of the brain. Adjacent sections were stained for either 
a combination of βIII Tubulin and BrdU in order to identify neuronal hotspots 
of mitochondrial biogenesis, or VDAC-1 and BrdU to perform mitochondrial 
biogenesis analysis as described in Chapter 3. The identity of neuronal niches 
was determined using histological landmarks. 
 
Image acquisition: 
Fluorescent  labelling  was  observed  through  a  LSM  5  Pascal  confocal 
microscope (Zeiss, Oberkochen, Germany) and images were recorded with 
the  Pascal  software  (Zeiss).  All  image  analysis  was  done  using  Image  J 
(NCBI, USA) and corresponding plug-ins. All staining was checked for non-
specific  antibody  labelling  using  control  slides  without  primary  antibody  or 
without  secondary  antibody  or  without  fluorescently  labelled  streptavidin.  
None of the controls showed any signs of nonspecific fluorescence. 
Analysis:	 ﾠ
The images from the first set of staining using βIII Tubulin and BrdU were 
used to identify neuronal niches containing mitochondrial BrdU signal. Images 
of section stained with antibody were analysed in 3D stacks collected with 	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optical sections 1μm apart and analysed using 3D Object counter using FIJI 
(ImageJ).  The  analysis  was  represented  as  the  percentage  of  particles  of 
VDAC-1,  which  also  showed  positive  staining  for  BrdU  (as  described  in 
Appendix). Slides from every animal were analyzed using the same settings 
normalized against a positive control section from the small intestine. Laser 
power, aperture of iris and PMT gain were kept consistent for the collection of 
images across the whole experiment. The threshold used for the analysis of 
particles was also kept consistent. Samples were processed and analyzed 
from  5  separate  animals  treated  in  exactly  the  same  protocol.  The 
mitochondrial biogenesis signal was then averaged from the 5 animals from 
comparable  neuronal  niches  and  analyzed  for  statistical  significance  using 
ANOVA. 
 
A similar analysis was performed for the dorsal root ganglion sensory cells 
and retinas. Retinas were not examined using 3D because of the frailty of the 
tissue. 2D particle count was performed on a ‘maximum intensity’ Z projection 
of the section imaged using 1μm optical sections. This may have resulted in 
the loss of some signal. Qualitatively the BrdU reached all parts of the body 
as  suggested  by  the  mitotic  signal,  which  appears  in  proliferating  glia 
observed in the CNS as well as the PNS. 
Results 
	 ﾠ
In order to screen for regions, we scanned sections of rat brains, which had 
been dosed with BrdU (2 x 200 mg/kg) 24 hours before culling. No signal was 
detected  in  non-neuronal  cells,  and  within  the  neuronal  types  there  were 	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areas of high levels of mitochondrial biogenesis. We then tried to identify the 
neuronal  types  using  stereotaxic  co-ordinates  and  neuronal  morphology. 
Neurons were identified using anti-beta III tubulin antibody and then the BrdU 
analysis was performed in adjacent sections using VDAC-1.  
 
The pharmacokinetic profile of BrdU in the animals allows for the detection of 
replicating mitochondrial DNA only in certain cells and not at all in all other 
cells, suggesting a large difference in the turnover occurring in certain cell 
types.  Although  most  neurones  show  little  to  no  turnover,  a  few  neuronal 
niches showed large amounts of BrdU being picked up by mitochondrial DNA. 
Histological landmarks and cellular morphology were used to identify these 
regions.  Large optical scans which were digitally tiled together, from regions 
of the brain stained against neuronal marker βIII-tubulin and BrdU were used 
to  visualize  neuronal  niches,  which  had  varying  degrees  of  BrdU  in  the 
cytoplasm. Examples of these are shown in Figures 1, 2 and 3.  
 
  
Figure 1: Optical section through a scanned image of the hippocampal CA1 
region. βIII-tubulin stained in red and BrdU in green. The inset image shows a 
high magnification depicting small BrdU-labelled particles in the cytoplasm of 
cells. Bigger green structures (white arrow) mark proliferating nuclei.  
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Figure 2: Optical section through a scanned image of the nucleus accumbens 
stained with anti-βIII tubulin antibody (red) and anti-BrdU antibody (green) The 
small box contains a high magnification image depicting small BrdU-labelled 
particles in the cytoplasm of cells. Bigger green structures mark proliferating 
nuclei.  
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Figure 3: Optical section through a scanned image of the motor cortex region. 
βIII-tubulin stained in red and BrdU in green. The inset image shows a high 
magnification  depicting  very  few  small  BrdU-labelled  particles  in  the 
cytoplasm of cells.  	 ﾠ 119	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Figure 4 The panel shows confocal images of sections of brain tissue from 
different regions imaged at the same magnification. The neurones are marked 
by neuronal marker Beta III Tubulin (red) and BrdU (green). Some regions 
show more cytoplasmic BrdU than others and some show none at all. (A) 
substantia  nigra,  (B)  ventral  tegmental  area  (C)  raphe  nuclei  (D)  nucleas 
accumbens,  (E)  dentate  gyrus  of  the  hippocampus  (F)  CA1  region  of  the 
hippocampus 
 
Other neuronal cell types outside the brain were also processed and imaged, 
specifically,  the  retina  and  dorsal  root  ganglion.  Samples  of  these  tissue 
regions  were  selected  because  they  are  susceptible  to  neurodegenerative 
pathology mediated by mitochondrial damage, such as in Leber’s hereditary 
optic neuropathy and diabetic neuropathy.   Certain regions of the brain that 
showed  large  mitochondrial  DNA  biogenesis  include  the  hippocampus, 
nucleus accumbens core, substantia nigra in the brain. Other regions showed 
very little labelling such as in the motor cortex (Figure 4).  
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Certain layers of the eye such as the retinal ganglion layer and outer layer 
show mitochondrial DNA biogenesis (Figure 5). In previous chapters motor 
neurones have been shown to pick up large mitochondrial biogenesis signal 
with this dosing regimen of BrdU. Additionally, the sensory neurons contained 
in the dorsal root ganglion also exhibited large BrdU signal in the cytoplasm 
as shown in Figure 5.  
 
	 ﾠ 
Figure 5: Sensory neurons also show incorporation of BrdU (Green) in beta 
III-tubulin  marked  neurones  (red).  (A)  shows  a  section  through  the  retinal 
layers. The retinal ganglion cells (RGC) and outer later (OL) show the most 	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BrdU labelling. (B) Shows sensory cells in the dorsal root ganglion with also a 
large turnover signal.  
 
The dopaminergic neuronal niches were of particular interest as they have 
been  implicated  in  primary  mitochondrial  disease  such  as  Parkinson’s 
disease. However, the dopaminergic neurones of the substantia nigra (SN) 
are susceptible to more degeneration than those of the ventral tegmental area 
(VTa).  This  mitochondrial  biogenesis  signal  from  these  two  regions  is 
observed to be vastly different (Figure 6). Tissue sections from these regions 
were stained for the dopaminergic marker tyrosine hydroxylase and BrdU to 
confirm  the  identity  of  the  neurones  and  the  SN  showed  far  more  mtDNA 
replication  signal  than  the  VTa.  It  may  be  postulated  that  a  constitutively 
higher  rate  of  mitochondrial  biogenesis  in  the  SN  compared  with  the  VTa 
could underlie the accumulation of mitochondrial damage. That is to say that 
when faced with a defect in the mitophagy pathway, as observed with many 
genetic  forms  of  Parkinson’s  disease,  the  SN  neurones  may  be  rendered 
vulnerable to accumulating clonally expanded dysfunctional mitochondria 	 ﾠ 122	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Figure 6: Section from brain tissue from the Substantia Nigra (A) and Ventral 
Tegmental Area (B). Immunohistochemical labelling for dopaminergic marker 
tyrosine hydroxylase (TH) in red and BrdU (green) 
 
Tissue  sections  from  the  CNS  and  PNS  were  tested  for  mitochondrial 
biogenesis signal as described in Appendix. We found that the percentage of 
mitochondria  picking  up  BrdU  signal  in  different  regions  of  the  CNS  was 
consistent across tissue harvested from several animals (Figure 7). Including 
the complete lack of signal from certain types of neurones. A good example 
were the sertonergic neurones of the raphe nuclei. Raphe nuclei neurones 
(Figure 9) are of similar size as the SN neurones. However, no mitochondrial 
biogenesis  signal  was  detected  in  the  cell  bodies.  These  observations 
suggest that the rate of mitochondrial biogenesis is defined by the metabolism 
and cellular identity of a neuron.  
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  Figure 7: When averaged over 5 animals, a few regions emerge as having 
statistically  more  BrdU  tagged  biogenesis  compared  with  control  regions. 
nucleus accumbens, hippocampus, substantia nigra, motor neurones, sensory 
neurones.  showed  significantly  higher  mitochondrial  biogenesis  than 
serotonergic  neurones  of  the  raphe  nuclei;  tested  by  one  –way  ANOVA, 
p=0.00045  
	 ﾠ	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Figure 8: Optical section through a scanned image of Raphe Nuclei. βIII-
tubulin  stained  in  red  and  BrdU  in  green.  The  inlaid  image  shows  a  high 
magnification depicting very few small BrdU labelled particles in the cytoplasm 
of cells. Bigger green structures mark proliferating nuclei.  
 
Due to the highly compact nature of retinal cell layers and cellular anatomy, 
the mitochondrial biogenesis analysis using the previously described method 
was not possible in this tissue. However, by qualitative observation we believe 
that the level of mtDNA replication in the retinal ganglion cell is high (Figure 
5A).  	 ﾠ 125	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Discussion 
Studies of mitochondrial biology in have shown that mitochondrial activities go 
beyond bioenergetics. A picture emerges in which mitochondrial biogenesis, 
mitophagy,  migration,  and  morphogenesis  are  crucial  for  brain  function. 
Understanding  of  these  new  aspects  of  mitochondrial  function  will  provide 
insights  into  brain  development  and  neurological  disease,  and  enable 
discovery and development of new strategies for treatment. 
 
Our  observation  that  the  dopaminergic  niches  show  high  levels  of 
mitochondrial DNA biogenesis is is particularly important from the perspective 
of  understanding  mitochondrial  dysfunction  in  Parkinson’s  disease. 
Parkinson's disease (PD) is a chronic neurodegenerative movement disorder 
characterized by the progressive and massive loss of dopaminergic neurons 
by neuronal apoptosis in the substantia nigra pars compacta and depletion of 
dopamine  in  the  striatum,  which  lead  to  pathological  and  clinical 
abnormalities.  Cellular  processes  including  oxidative  stress,  mitochondrial 
dysfunction, and accumulation of α-synuclein aggregates are considered to 
contribute to the pathogenesis of Parkinson's disease.  
 
Accumulation  of  mitochondrial  DNA  deletions  is  observed  especially  in 
dopaminergic neurons of the substantia nigra during ageing and even more in 
Parkinson's  disease  (Bender  et  al.,  2006;  Kraytsberg  et  al.,  2006).  The 
resulting mitochondrial dysfunction is suspected to play an important role in 	 ﾠ 126	 ﾠ
neurodegeneration.  Recently  it  has  been  shown  that  catecholamine 
metabolism  drives  the  generation  and  accumulation  of  these  mitochondrial 
DNA  mutations  (Neuhaus  et  al.,  2014).  Dopamine  treatment  of  terminally 
differentiated  neuroblastoma  cells,  as  well  as  stimulation  of  dopamine 
turnover in mice over-expressing monoamine oxidase B, both induce multiple 
mitochondrial  DNA  deletions.  These  mechanisms  identify  catecholamine 
metabolism as the driving force behind mitochondrial DNA deletions, probably 
being  an  important  factor  in  the  ageing-associated  degeneration  of 
dopaminergic neurons.  
 
Mitochondrial  dysfunction  in  the  form  of  reduced  bioenergetic  capacity, 
increased oxidative stress and reduced resistance to stress, is observed in 
several Parkinson's disease models. However, identification of the recessive 
genes  implicated  in  Parkinson's  disease  has  revealed  a  common  pathway 
involving mitochondrial dynamics, transport, turnover and mitophagy. While 
the mtDNA mutations are shown to occur in both dopaminergic niches, it is 
evident  that  the  substantia  nigra  neurones  are  more  susceptible  to 
neurodegeneration.  
 
Our observation suggests that the dopaminergic SN cells maintain a higher 
mitochondrial  biogenesis  rate  compared  with  dopaminergic  VTa  neurones 
(Figure 6). This may suggest that by the sheer replicative rate these neurones 
are more susceptible to accumulating clonal expansion of mutant deletions. 	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Or that, as suggested by Mosharov et al (Mosharov et al., 2009), the higher 
dopaminergic concentrations in the SN result in more mitochondrial damage, 
which needs to be compensated for, and hence the mitochondrial biogenesis 
rate  is  high.  Unless  the  rate  of  biogenesis  is  very  strongly  coupled  to  the 
mitophagy pathway this system will remain susceptible to degeneration. In 
addition,  it  is  conceivable  that,  with  mitochondrial  dysfunction  induced  by 
higher mitochondrial DNA deletions levels in substantia nigra pars compacta 
neurons, the Ca
2+ buffering capacity of the organelles may well be impaired, 
thus  worsening  the  situation.  Alternatively,  levels  of  mitochondrial  DNA 
deletions  and  ensuing  mitochondrial  dysfunction  may  be  similar  in  ventral 
tegmental area and substantia nigra pars compacta neurons, however, the 
high energy requirement of Ca
2+ homeostasis in the latter, and the resulting 
reliance on mitochondria, could make them more vulnerable (Surmeier and 
Schumacker,  2013).  There  is  recent  evidence  suggesting  that  PPAR-γ 
(peroxisome  proliferator-activated  receptor  -  gamma)  agonist  fenofibrate  is 
effective in alleviating the effects of damage in the rodent MPTP model of 
Parkinson’s  disease  (Barbiero  et  al.,  2014).  While  PPAR-γ  agonists  are 
messy drugs with several molecular targets, a major target is the induction of 
mitochondrial  biogenesis  via  the  PPAR-γ  receptor.  This  along  with  our 
observation of the substantia nigra cells having high mitochondrial biogenesis 
opens up a potential therapeutic avenue. 
 
Leber's hereditary optic neuropathy is a maternally inherited blinding disease 
caused as a result of homoplasmic point mutations in complex I subunit genes 	 ﾠ 128	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of mitochondrial DNA. It is characterized by incomplete penetrance, as only 
some  mutation  carriers  become  affected.  There  is  recent  evidence  which 
supports increased mitochondrial biogenesis in carriers may overcome some 
of  the  pathogenic  effect  of  mitochondrial  DNA  mutations  (Giordano  et  al., 
2014). We have observed that normally the retinal ganglion layer, which is 
susceptible to damage in LHON, shows high mitochondrial biogenesis.  
 
Mitochondria in motor neurones are also observed to have high biogenesis 
signal.  These  neurones  are  susceptible  to  damage  in  the  SOD1  mutation 
which  leads  to  amyotrophic  lateral  sclerosis  (ALS).  This  enzyme  is  an 
antioxidant  in  the  matrix  of  mitochondria,  which  protects  ROS  induced 
damage to mitochondrial DNA, proteins and lipids. Recent evidence suggests 
that  resveratrol  is  effective  in  reducing  some  of  the  damage  in  a  SOD1 
knockout  model  of  ALS.  Resveratrol  protects  neurones  by  increasing 
activation and expression of Sirtuin 1 (SIRT1) and AMPK in the spinal cord 
and inducing mitochondrial biogenesis (Mancuso et al., 2014) 
 
In Alzheimer’s disease, where a complicated pathology results in large scale 
degeneration, the hippocampus is known to be affected quite early on and 
strongly in the disease. In a recent study which highlighted the differences in 
gene  expression  amongst  Alzheimer’s  affected  brains,  mild  cognitive 
impairment  brains  and  healthy  brains,  the  mitochondrial  genes  were 
implicated strongly (Berchtold et al., 2014). Furthermore, mtDNA copy number 
is reduced and mitochondrial biogenesis is disrupted in the hippocampi (Rice 	 ﾠ 129	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et al., 2014). This is corroborated in our observation that the hippocampus 
has a constitutively high level of mitochondrial biogenesis and we postulate 
that this may be reduced in affected brains. 
 
Sensory neurones are affected in peripheral neuropathies such as diabetic 
neuropathy.  Literature  suggests  that  the  pathology  is  manifested  by  an 
imbalance of mitochondrial lifecycle (Vincent et al., 2010). We also observe a 
high turnover rate of mitochondrial biogenesis in doral root ganglion sensory 
neurones.  
 
The emerging theme is that niches of neurons which show constitutively high 
mitochondrial biogenesis have a susceptibility to degeneration which can be 
precipitated by a variety of external insults- genetic, inflammatory, energetic 
demands. The data represented in this study are the first visualization of the 
unique nature of the high turnover of mitochondrial DNA in certain neuronal 
populations. The niches identified can be targets for mitochondrial lifecycle 
modulating  drugs  in  diseases  in  which  the  neurones  degenerate. 
Furthermore, I have described an effective method in being able to evaluate 
changes  in  mitochondrial  biogenesis  rate  using  BrdU  if  indeed  these 
therapeutic strategies need to be assessed at a cellular level. 
 
The question about why certain populations of neurons degenerate in genetic 
forms of neurodegenerative diseases while all cells carry the mutations has 
long  plagued  neuroscientists.  We  speculate  the  rate  of  mitochondrial 
biogenesis and in turn the ‘dependence’ of the cell on mitochondrial function 	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may be one aspect of predicting which cells are susceptible to degenerative 
pathology as a consequence of mitochondrial dysfunction.    	 ﾠ 131	 ﾠ
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Chapter 6: Discussion 
New method showing somatic mitochondrial nursery 
The  overall  aim  of  this  thesis  was  to  profile  the  process  of  mitochondrial 
biogenesis in the mammalian nervous system. To quantify the percentage of 
mitochondrial undergoing active growth, I developed a method using mtDNA 
replication as a surrogate marker for mitochondrial biogenesis.  In this study I 
showed  that  BrdU  could  be  used  as  a  marker  for  mitochondrial  DNA 
replication and present a tool to study the life cycle of mitochondria in the 
mammalian CNS in vivo. I have described a precise method for conducting 
these studies. Furthermore, I have investigated the birth of new mitochondria 
in motor neurons in the spinal cord. This work is an important step towards 
understanding  conditions  under  which  the  balance  of  mitochondrial 
biogenesis and mitophagy (Figure 1) is disturbed.  
 
While previous studies have used BrdU to target mitochondrial DNA in vitro 
(Calkins et al., 2011; Calkins and Reddy, 2011b; Magnusson et al., 2003), this 
is  the  first  reported  use  of  BrdU  and  enhanced  immunohistochemistry 
investigating mitochondrial DNA with spatial and temporal resolution in vivo. I 
found that with 6-hour exposure to a reasonable blood plasma concentration 
of BrdU, I can achieve clear labelling of replicating DNA in mitochondria and 
validate this methodology reproducibly in vitro. The methodology established 
here, is relevant for not just MS but also other neurological disorders in which 	 ﾠ 133	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mitochondrial pathology manifests. It can also helps identify cellular niches in 
the CNS with high turnover of mitochondria. 
 
Figure 1: Overview of the balance of mitochondrial biogenesis and mitophagy, 
the modulation of which determines the mitochondrial content and turnover in 
a cell. The balance of both is what should be achieved for optimum health of 
the mitochondrial network. Future efforts are needed to identify the signalling 
pathways  which  can  be  modulated  to  maintain  this  balance  and  also  the 
changes that occur under pathological conditions.  
 
From our study of BrdU incorporation into motor neurons of the spinal cord, 
we  observed  that  a  distinct  pattern  emerged.  We  interpret  these  time 
dependent  changes  in  new  mitochondrial  DNA  as  representative  of  the 
biogenesis of mitochondria in these cells. We observed an increase in BrdU 
labelling in the first four hours after injection of BrdU, which we suggest is the 
period over which incorporation of BrdU into mitochondrial DNA takes place. 
Following which, we observed a progressive decrease in labelling to 9.5 hours 
post injection of BrdU (the longest period examined in this experiment). These 
data suggest that the newly formed DNA has begun to be distributed into the 
rest of the mitochondrial network outside of the cell body. Accordingly, when 
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some of the sciatic nerve sections were labeled for BrdU and porin, the BrdU 
label appeared only in the sections from animals, which were sacrificed 9.5 
hours  after  the  BrdU  injections.  We  interpret  this  to  indicate  newly  formed 
mitochondrial DNA getting distributed through the network.  We did not see 
new mitochondrial DNA in the sciatic nerve in the early time points of the 
study. This suggests that in these spinal neurons the mitochondria are only 
being formed in cell bodies; contrary to what has been observed in vitro (Amiri 
and Hollenbeck, 2008) 
 
Over the longer time period (21 days), we observed that the amount of BrdU 
labelled mitochondrial DNA in the cell body reduced over time up to five days, 
and then seemed to go up again at 11 days (but not statistically significant). If 
correct, this finding may suggest that this newly formed mitochondrial DNA 
has been moved away from the cell bodies, as part of the process by which 
new mitochondria are supplied to distal parts of cells. Further investigation is 
needed  to  confirm  whether  these  mitochondria  return  to  cell  body  for 
autophagy in due course of time. The duration of the mitochondrial life cycle is 
likely to be different in different types of cells and with the BrdU tag we now 
have  a  method  to  study  this  temporally.  There  is  a  possibility  that  DNA 
containing  BrdU  is  targeted  for  autophagy  earlier  than  the  wild  type  DNA. 
Since we did not observe any obvious cellular death or atrophy at any of the 
time points, we assume that at the least, BrdU containing mitochondria did not 
result in cell death.  
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The  process  of  mitochondrial  biosynthesis  is  highly  interlinked  with 
mitochondrial fission, and therefore BrdU-labelled mitochondrial DNA content 
reflects  both  mitochondrial  biosynthesis  and  fission.  Mitochondrial  DNA 
replication  occurs  in  existing  organelles  largely  within  the  cell  soma.  After 
DNA replication, the organelle will undergo Drp1 mediated fission to produce 
two daughter mitochondria. Both of these daughter mitochondria are expected 
to  carry  the  BrdU-labelled  DNA.  Without  a  fission  event  to  separate  the 
mitochondria,  BrdU-labelling  would  occur  as  a  single  punctum  with  high 
intensity. Under conditions of enhanced Drp1 activation and normal mtDNA 
synthesis, the number of BrdU puncta would be increased. 
 
MtDNA  synthesis  is  known  to  occur  largely  in  the  cell  body  but  there  is 
evidence  that  it  occurs  in  neurites  as  well  (Amiri  and  Hollenbeck,  2008). 
Presented data showed that the majority of BrdU-labeled mitochondria occur 
within  or  very  near  the  cell  body,  supporting  the  notion  that  mitochondrial 
biogenesis is largely dependent on factors within the soma. When healthy, 
newly  formed  mitochondria  are  available  for  anterograde  transport  to  the 
distal regions of the neuron, where they will supply the necessary ATP to 
satisfy  the  high-energy  demands  of  synaptic  activity.  However,  as  in  this 
study, in diseased neurones or in neurons exposed to toxins, mitochondria 
are excessively fragmented and produce large numbers of small, defective 
mitochondria. These defective mitochondria stay mostly in the soma and do 
not  (or  perhaps  are  unable  to  transport)  to  distal  regions  of  the  neurons, 
hence depriving nerve terminals of ATP. This ATP deprivation may ultimately 	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decrease  synaptic  activities  and  increase  synaptic  degeneration.  The 
presence of the somatic nursery could also present a peculiar phenomenon in 
diseases of the spinal cord. The motor neurone cell bodies are contained in 
the grey matter of the spinal cord. If indeed the ‘mother’ mitochondria are 
present  in  the  soma,  damage  to  this  pool  of  mitochondria  can  have 
devastating effects on the population of mitochondria in the cell. This process 
could be postulated as a towards clonal expansion of damaged mtDNA.  
 
In summary, BrdU-labelling of mtDNA synthesis allowed us to assess newly 
synthesized  mtDNA  in  the  cell  body  neurones.  Previous  studies  have 
established clonal expansion of mutant mtDNA as a feature of MS (Campbell 
et  al.,  2011).  While  high  oxidative  stress,  hypoxia,  inflammation  and  high 
levels of cytokines might be present in different parts of the brain and CNS, 
the  proximity  of  a  tissue  insult  to  the  somatic  mitochondrial  nursery  could 
render a neurone vulnerable to accumulating mitochondrial DNA damage. It 
maybe postulated then that protecting the somatic pool of mitochondria from 
damage in the long run more effective in therapy.  
Hot-ﾭ‐spots	 ﾠof	 ﾠneuronal	 ﾠmitochondrial	 ﾠbiogenesis	 ﾠ
Several neuronal niches have been identified in this thesis, which maintain a 
constitutively high rate of mitochondrial biogenesis. As such, this presents an 
opportunity to identify molecular players, which modulate and maintain this 
high  level  of  mitochondrial  biogenesis.  For  instance,  in  the  future,  a 
combination of laser dissection microscopy and microarray technology can be 
used to find genes that help maintain a high rate of mitochondrial biogenesis. 	 ﾠ 137	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These then become targets for modulation from the perspective of not just 
therapeutic intervention but also understanding the signalling pathways.  
 
The high-biogenesis neuronal niches identified in this study were found to be 
tightly  associated  with  neurodegenerative  disease.  This  presents  an 
opportunity  to  understand  why  these  cells  maintain  this  high  rate  of 
mitochondrial biogenesis. Whether it is simply related to the size of neurites, 
or also to other constraints to metabolism.  
Reactivity	 ﾠto	 ﾠbioenergetic	 ﾠchanges	 ﾠ	 ﾠ	 ﾠ
Previously, in cultured muscle cells it was found that an increase in electrical 
activity could quickly initial mitochondrial biogenesis (Ding et al., 2012). We 
described a similar observation in motor neurones and sensory neurones. It 
has been observed that following electrical activity; mitochondria are trafficked 
to  the  peripheral  regions  of  the  neurone  (Sajic  et  al.,  2013).  Also,  the 
phenomenon  of  transmitophagy  has  been  observed  in  retinal  neurones, 
where mitochondria move from neurones to astrocytes for degradation (Davis 
et al., 2014). Together, these three observations present a picture that the 
mitochondrial network in long neurones may be a combination of an assembly 
line  and  a  recycling  unit,  where  mitochondria  are  made  in  the  cell  body, 
trafficked down the axons to distal parts and then damaged mitochondria do 
not return to the cell body for degradation but rather are degraded by locally 
present astrocytes.  
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Transcriptional	 ﾠmodulation	 ﾠof	 ﾠmitochondrial	 ﾠbiogenesis	 ﾠ
PGC-1α is now increasingly being recognized as an important therapeutic 
target  for  neurodegenerative  disorders.  As  discussed  above,  PGC-1 α 
expression  and/or  function  is  impaired  in  many  major  neurodegenerative 
diseases; therefore, pharmacologic/transcriptional activation of the PGC-1α 
pathway is expected to have neuroprotective effects. Recently, Da Cruz et al. 
(2012)  showed  that  increasing  PGC-1α  activity  in  muscle  in  a  transgenic 
mouse model of ALS caused by a mutation in SOD1 is able to sustain muscle 
function throughout the disease course, although survival was not extended 
(Da Cruz et al., 2012). Another potential approach to activating the PGC-1α 
pathway,  and  thereby  improving  mitochondrial  function,  is  via  activation  of 
PPARs.  The  PPARs  are  a  subfamily  of  nuclear  receptors  that  are  ligand-
modulated transcription factors that regulate gene expression programmes of 
metabolic  pathways.  PPAR  agonists  increase  oxidative  phosphorylation 
capacity in mouse and human cells and enhance mitochondrial biogenesis. 
Both pioglitazone and rosiglitazone, which are PPAR-γ agonists, were shown 
to  exert  beneficial  effects  in  in  vitro  and  in  vivo  models  of  PD  and  AD 
(Chaturvedi and Beal, 2008). 
 
 Sirtuins  (silent  information  regulators,  SIRT)  are  members  of  the  NAD+-
dependent histone deacetylase family of proteins in yeast, and its homologs in 
mice  and  humans  participate  in  a  variety  of  cellular  processes,  including 
mitochondrial  functions,  cellular  metabolism,  energy  metabolism, 
gluconeogenesis,  cell  survival,  and  aging.  Although  the  role  of  sirtuins  in 	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promoting  lifespan  extension  in  non-mammalian  organisms  has  been 
contested recently, there is strong evidence to suggest that sirtuins are an 
integrative link between metabolic control and transcriptional regulation, and 
the  role  of  SIRT1  in  activating  the  master  regulator  PGC-1α  is  largely 
accepted. Increased intracellular NAD+ concentrations activate SIRT1 in brain 
after  caloric  restriction  resulting  in  a  reduction  in  amyloid  pathology  in  a 
mouse  model  of  AD;  increased  SIRT1  protects  against  hippocampal 
degeneration in a mouse model of AD, and direct injection of SIRT1 lentivirus 
in  the  hippocampus  of  AD  transgenic  mice  produces  significant 
neuroprotection (Chaturvedi and Beal, 2008). SIRT1 activation by resveratrol 
increases the survival of motor neurons in transgenic ALS mice and reduces 
learning  impairments  and  neurodegeneration  in  AD  mouse  models,  by 
decreasing the acetylation of the SIRT1 substrates PGC-1α and p53 (Song 
et al., 2014). Overexpression of SIRT1 improves motor function and reduces 
brain atrophy, in transgenic mouse models of HD (Jiang et al., 2012a).  
 
 AMP-activated protein kinase (AMPK) is a Ser/Thr kinase that is activated as 
a consequence of increased AMP levels, reflecting low ATP availability and 
low energy reserve. AMPK activation results in a cascade of phosphorylation-
dependent adaptive modifications of several factors, including PGC-1α, to 
switch  on  the  catabolic  pathways  (such  as  fatty  acid  oxidation  and 
mitochondrial respiratory chain activity) to produce ATP, while simultaneously 
shutting  down  energy-consuming  anabolic  processes.  5-Aminoimidazole-4-
carboxamide ribonucleoside (AICAR) is a compound that has been used to 
activate  PGC-1 α   through  AMPK.  It  does  so  by  generating  inosine 	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monophosphate, which acts as an AMPK agonist by mimicking AMP. AICAR 
was shown to inhibit tau phosphorylation in an in vitro model of AD; however, 
AMPK activation by AICAR was shown to produce adverse effects in R6/2 HD 
mice  in  that  it  enhanced  brain  atrophy,  neuronal  loss,  and  aggregate 
formation  in  the  striatum.  Recently,  it  was  shown  that  AMPK  activity  is 
increased  in  spinal  cord  cultures  expressing  mutant  SOD1,  as  well  as  in 
spinal  cord  lysates  from  mutant  SOD1  mice  (Lim  et  al.,  2012b).  Reducing 
AMPK  activity  either  pharmacologically  or  genetically  prevented  mutant 
SOD1-induced motor neuron death in vitro (Lim et al., 2012b). Metformin is 
another AMPK activator and known inducer of mitochondrial biogenesis was 
shown to be effective in male HD transgenic mice in that it prolonged survival 
and decreased hind limb clasping (Ma et al., 2007).  
 
 ROS  damage  to  mitochondria  is  well  known  in  all  of  the  major 
neurodegenerative  disorders;  therefore,  therapies  targeting  the 
Nrf2/antioxidant response element (ARE) pathway are of particular interest. 
Neuronal  cultures  derived  from  Nrf2  knockout  mice  show  increased 
susceptibility  to  oxidative  damage,  as  well  as  damage  produced  by 
mitochondrial electron transport gene complex inhibitors such as MPP+ and 
rotenone.  Nrf2-deficient  mice  show  increased  susceptibility  to  the 
mitochondrial  toxins  MPTP  and  3-NP.  The  synthetic  triterpenoid  CDDO 
methylamide  (CDDO-MA),  which  is  a  potent  activator  of  the  Nrf2/ARE 
signalling  pathway  was  tested  (Yang  et  al.,  2009).  CDDO-MA  produced 
marked  protection  in  the  3-NP  rat  model  and  both  the  acute  and  chronic 
MPTP  mouse  models.  CDDO-MA  exerted  significant  protection  against 	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tertbutylhydroperoxide-induced ROS in vitro. It increased the expression of 
genes  involved  in  mitochondrial  biogenesis,  as  well  as  those  involved  in 
glutathione  synthesis  and  in  the  expression  of  antioxidant  enzymes. 
Triterpenoids also protect in transgenic mouse models of HD (Escartin and 
Brouillet, 2010; Stack et al., 2010).  
 
  The beneficial effects of resveratrol and SIRT1 that were observed in several 
mouse models of neurodegenerative diseases cannot be overlooked, and the 
quest for small-molecule activators of sirtuins with potential neuroprotective 
effects should continue along with other avenues of initiating mitochondrial 
biogenesis. The collective observations and findings described in this thesis 
present an opportunity to identify molecular targets which modulate 
mitochondrial biogenesis, assess the level of mitochondrial biogenesis under 
different conditions and explore the possibility of protecting certain neuronal 
niches against damage by mitochondrial life cycle changes.    	 ﾠ 142	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Appendix 
Materials	 ﾠ
1. Phosphate Buffered Saline (PBS) 
0.1 M PBS was prepared either in a stock solution of 10 times concentration 
and then diluted 1:10 with deionised water just before use or made at isotonic 
concentration just before use. All salts were measured on a chemical balance, 
and then dissolved in deionised water using a magnetic stirrer. The following 
table describes the concentration of different components used.  
Salt 
Molarity 
(mM) 
g/l  for 
1x 
solution 
g/l  for 
10x 
solution 
NaCl  137  8.01  80.1 
KCl  2.7  0.2  2 
Na2HPO4.2H2O  10  1.78  17.8 
KH2HPO4  2  0.27  2.7 
pH 7.4 
 
For convenience, small quantities of PBS were made by dissolving PBS tablets 
(Sigma Aldrich) in deionised water – 1 tablet per 200 ml.  
 
 
 	 ﾠ 143	 ﾠ
2. Phosphate Buffer (PB) 
0.1 M Phosphate buffer was made by dissolving 3.1 g of NaH2PO4.H2O and 
10.9 g of Na2HPO4 in 1 l of deionised water.  
 
3. Saline for Injection  
For small quantities packaged sterile saline was used from plastic vials. For 
experiments requiring a large amount saline was prepared by dissolving 0.9 g 
of NaCl in 1 l of deionised water and then autoclaving the solution to render it 
sterile.  
 
4. 4% Parafomaldehyde (PFA) 
For 1 l of 4% PFA, 600 ml of deionised water was placed in a glass beaker on 
a stir plate in a ventilated hood along with a temperature probe. The water was 
heated to about 50°C and then 40 g of paraformaldehyde powder was added. 
The mixture was heated and stirred up to 60 °C. The pH was slowly raised by 
added 1 N NaOH solution drop-wise with continuous stirring. Once the solution 
cleared, the mixture was cooled and filtered. This filtered solution was mixed 
with 300 ml of deionised water into which the full salt composition of 1 l PBS 
(either  from  salts  as  described  above  or  5  PBS  tablets)  had  already  been 
dissolved. The full mixture was then checked for pH and the volume made up 
to 1 l in a volumetric flask. This solution was made up fresh for all perfusions or 
split  in  aliquots  of  50  ml  and  stored  at  -80°C  for  fixing  slides  before 
immunohistochemistry.  
 
5. Sucrose solution for cryoprotection 	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Sucrose was dissolved in PB in increasing concentrations to make solutions for 
graded cryoprotection of post fixed neural tissue. 10, 20 or 30 g of sucrose was 
dissolved in PB and made up to a volume of 100 ml.  
 
6. Triton X solution for immunohistochemistry 
For permeabilization of tissue 0.3% Triton x-100 was prepared by dissolving 
300 μl of Triton X-100 (Sigma Aldrich) in 100 ml of PBS by gentle stirring on a 
magnetic stirrer or roller.  
 
7. Tween 80 solution for immunohistochemistry 
0.3% Tween solution was prepared by dissolving 300 μl of Tween 80 (Sigma 
Aldrich) in 100 ml of PBS by gentle stirring on a magnetic stirrer or roller.  
 
8. Blocking Buffer 
Blocking buffer was prepared by gently mixing a secondary antibody matched 
animal sera in 5% concentration. For instance 1 ml of goat serum made up to a 
volume  of  20  ml  using  PBS,  stirred  gently.  Where  two  different  sera  were 
required the quantity of each was halved to make up a total of 5% volume in 
the solution. All sera were purchased either from Vector Labs or Sigma 
Method	 ﾠfor	 ﾠdetecting	 ﾠmitochondrial	 ﾠbiogenesis	 ﾠ
Mitochondrial biogenesis was analysed using 3D confocal images of sections 
from rodent tissue stained for detecting BrdU and VDAC-1 as described. In 
experiments described in chapters 3, 4, and 5, the percentage of VDAC-1 
positive particles that also showed BrdU staining was used as a measure of 	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mitochondrial  biogenesis.  Images  were  acquired  using  similar  imaging 
parameters and individual neurones of interest were scored for mitochondrial 
biogenesis  using  particle  analysis.  Neurones  presented  mitochondrial 
particles with small BrdU staining within those particles as seen in the series 
of  images  shown  in  Figure  1.  These  images  represent  one  single  motor 
neuron from the ventral horn of spinal cord. VDAC-1 signal is seen in red, the 
BrdU signal is seen in and colocolization is digitally visualized in yellow. The 
series of images is of a 3D reconstruction of the neurones made from 1 μm 
thick  optical  sections  acquired  in  two  colour  channels.  Each  consecutive 
image from A to J is rotated 40° from the previous image in the series.  
 
Analysis was performed on individual spectral channels.  First the neuron was 
identified manually by defining a region of interest as shown in Image 1 A. A 
fluorescence intensity threshold was set manually as shown in Image 2A and 
2B which collected only positive signal and not the background signal. This 
threshold was maintained for all images. Then the Image J plugin, 3D particle 
count, was used to count the number of particles across the stack of optical 
sections (Image 2C- Green, Image 2D- Red). These numbers were then used 
to calculate the extent of mitochondrial biogenesis. In this particular case the 
signal is (12/18) x 100 – 66.67%. 	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Figure 1: 3D rotation in series of one motor neurone in a spinal cord section 
from mouse. The section was labelled for VDAC-1 (red) and BrdU (green) and 
colocalization  is  seen  in  yellow.  The  white  dashed  line  in  panel  A  is  a 
representation of how a cell body was identified for analysis. 
 
 
   
Figure 2: The Image J plugin ‘particle count’ generates images as shown in 
this  panel.  Panel  A  is  the  raw  pseudocolored  image,  which  then  gets 
thresholded for intensity (panel B). The particles are counted in 3D and a 
count is generated. Panel C is the count for the BrdU signal and panel D 
shows count for the VDAC-1 signal for the same motor neurone cell body. 	 ﾠ 147	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